**Table F-1. Clinician administered PTSD scales, self-administered PTSD scales, remission, and loss of PTSD diagnosis**

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Acarturk et al., 2016[44](#_ENREF_44) | G1: EMDR-R-TEP G2: WL | HTQMean (SE at pre-tx; SD at post-tx and followup)G1 Pre-tx:2.63 (13.65)G1 Post-tx: 1.42 (0.07)G1 1 month FU: 1.57 (0.08)G2 Pre-tx: 2.47 (0.43)G2 Post-tx: 2.38 (0.08)G2 1 month FU: 2.38 (0.08)G1 vs G2 pre to post-tx p<0.001G1 vs G2 pre-tx to FU, p<0.001Treatment X Time, F = 1.33, p = 0.254 from post-tx to FUMean estimated difference, post-tx: -0.96 (95% CI, -1.18 to -0.74), p <0.001Mean estimated difference, 1 month FU: -0.81 (95% CI, -1.04 to -0.58), p <0.001 | IES-RMean (SE at pre-tx; SD at post-tx and followup)G1 Pre-tx:59.69 (13.65)G1 Post-tx:21.36 (2.76)G1 1 month FU: 25.87 (3.01)G2 Pre-tx: 62.55 (12.46)G2 Post-tx: 59.01 (2.92)G2 1 month FU: 60.37 (3.01)G1 vs G2 pre to post-tx p<0.001G1 vs G2 pre-tx to FU p<0.001Treatment X Time, F = 0.50, p = 0.483 from post-tx to FUMean estimated difference, post-tx: -37.65 (95% CI, -45.66 to 29.63), p <0.001Mean estimated difference, 1 month FU: -34.50 (95% CI, -43.25 to -25.76), p <0.001 | Remission NRLoss of Diagnosis based on MINI PTSD, n (%)G1 Post-tx: 30 (61)G2 Post-tx: 3 (6)X2 (df) = 33.31 (1), p <0.001OR = 24.21 (95% CI, 6.59 to 88.98)NNT=2 (95%CI, 1.4-2.5)G1 1 month followup: 24 (49)G2 1 month followup: 2 (4)X2 (df) = 25.34 (1), p <0.001X2 (df) = 25.34 (1), p <0.001OR = 22.56 (95% CI, 4.92 to 103.35)NNT=3 (95% CI, 1.9-5.7) |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Acosta et al., 2017[149](#_ENREF_149) | G1: Web CBT plus TAU (Thinking Forward and usual VA primary care services)G2: TAU, usual VA primary care services | NR | PCLTreatment by time interaction effect, NS for PTSD severity and PTSD symptoms during in-treatment period, Estimate: -0.09 (0.50)Treatment by time effect, NS for PTSD severity and PTSD symptoms contrasting in and post treatment period (period between post treatment and 3 month followup), Estimate: 0.40 (0.82) | RemissionClinically meaningful improvement on PCL PTSD symptoms (i.e., >10-point decrease)12 weeksG1:41.0%G2: 31.3%Chi-square, NS3-month followupG1: 37.5%G2: 29.7%Chi-square, NSNo longer reporting clinical levels of distress based on PCL distress (i.e., >50)12 weeksG1: 22.2%G2: 17.9%Chi-square, NS3-month followupG1: 17.9%G2: 23.4%Chi-square, NSLoss of Diagnosis: NR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Akuchekian et al., 2004[77](#_ENREF_77) | G1: Topiramate25 to 500 mg/day (sensitive patients started at 12.5mg/day)G2: Placebo | CAPSMean (SD)G1 Pre-tx: 50.70 (7.7)G1 Post-tx: 32.75 (8.2)G2 Pre-tx: 48.9 (9.13)G2 Post-tx: 46.62 (8.8)G1 vs. G2, p=0.00 (based on t-test) | NR | NRNR |
| Asukai et al., 2010[10](#_ENREF_10) | G1: CBT, exposure-based therapyG2: UC | CAPSAdjusted Mean (SE)G1 Pre-tx:84.58 (7.78)G1 Post-tx: 43.76 (8.43)G2 Pre-tx:84.33 (7.78)G2 Post-tx: 84.81 (7.96)At post: G1 vs. G2= p<0.01(based on t-test) | IES-RAdjusted Means (SE)G1 Pre-tx: 59.67 (5.06)G1 Post-tx: 21.15 (5.53)G2 Pre-tx: 59.75 (5.06)G2 Post-tx: 53.75 (5.20)At post: G1 vs. G2 = p<0.001 (based on t-test) | NRNR |
| Bartzokis et al., 2005[86](#_ENREF_86) | G1: Risperidone1 to 3 mg/day G2: Placebo | CAPSUnadjusted Change from baseline (SD)G1: -14.3 (16.7)G2: -4.6 (13.2) G1 vs. G2, p<0.05 | NR | NRNR |
| Basoglu et al., 2007[11](#_ENREF_11) | G1: CBT, exposure-based therapyG2: WL | CAPSMean (SD)G1 Pre-tx: 63.1 (10.1)G1 Week 4: 38.7 (18.7)G1 Week 8:30.2 (20.3) G2 Pre-tx: 62.3 (14.5)G2 Week 4: 54.5 (16.9)G2 Week 8: 49.1 (20.3)G1 vs. G2 at Week 4, p<0.01G1 vs. G2 at Week 8, p<0.01 | NR | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Batki et al., 2014[165](#_ENREF_165) | G1: Topiramate 25 to 300mgG2: Placebo  | NR | PCL totalBetween-group analysisWeeks 1 to 12 Avg.G1: 42.3 (16.0)G2: 49.0 (16.5)P p = 0.100, IRR = -9.01, 95% CI -19.8-1.80, % diff. = 14Main Effects of treatment, F (1,48) = 2.81, p = 0.100 | Remission NRLoss of PTSD diagnosis NR |
| Becker et al., 2007[183](#_ENREF_183) | G1: Bupropion100 to 300 mg/dayG2: Placebo | CAPSWithin-Group Mean Change (SD)(Baseline-Endpoint)G1: 12.33 (24.12) G2: 16.99 (11.26) Group effect, p<0.01 | DTSWithin-Group Mean Change (SD)(Baseline-Endpoint)G1: 13.22 (21.62)G2: 10.6 (29.20)  Group effect, p<0.05 | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Blanchard et al., 2003[36](#_ENREF_36) | G1: CBT-mixed G2: Supportive psychotherapyG3: WL | CAPSMean (SD)G1 Pre-tx: 68.2 (22.7)G1 Post-tx: 23.7 (26.2)G2 Pre-tx: 65.0 (25.9)G2 Post-tx:40.1 (25.7)G3 Baseline: 65.8 (26.6)G3 Post-tx: 54.0 (25.9)Group X Time at post-tx, p<0.001G1 vs. G2, p=0.002G1 vs. G3, p<0.001G2 vs. G3, p=0.012Including DropoutsGroup X Time at post-tx, p<0.001G1 vs. G2, p=0.013G1 vs. G3, p<0.001G2 vs. G3, p=0.052Group X Time, 3 mth FUp=0.048G1 continued to have lower scores than G2, p=0.003Decreases from post-tx to the 3 mth fu, NS | IESMean (SD)G1 Baseline: 40.4 (13.8)G1 Post-tx: 12.1 (14.9)G1 FU: 12.2 (13.6)G2 Baseline: 38.7 (20.9)G2 Post-tx: 27.4 (19.1)G2 FU: 24.0 (20.1)G3 Baseline:40.2 (15.9)G3 Post-tx: 36.6 (17.2)Post-txG1 vs. G2 & G3, p<0.01G2 vs. G3, NSPCLMean (SD)G1 Baseline: 54.4 (12.2)G1 Post-tx: 31.3 (14.1)G1 FU: 31.1 (14.2)G2 Baseline: 55.0 (14.7)G2 Post-tx: 43.8 (14.6)G2 FU: 40.8 (14.4)G3 Baseline: 55.9 (13.3)G3 Post-tx: 53.9 (14.1)Post-txG1 vs. G2 & G3, p<0.01G2 vs. G3, significantly greater change | NRImproved from PTSD to sub-syndromal PTSD or non-PTSDG1: 76.2%G2: 47.6G3: 23.8%3 month FUG1: 81%G2: 42.9% |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Boden et al., 2012[58](#_ENREF_58) | G1: Seeking Safety and TAUG2: TAU | NR | IES-RMean (SD)G1 Pre-tx: 46.8 (19.5)G1 Post-tx: 40.8 (20.9)G1 6 mth FU: 38.9 (16.7)G2 Pre-tx: 47.4 (16.3)G2 Post-tx: 42.4 (21.3)G2 6 mth FU: 36.5 (16.9)Between Group Differences, NSG1 Within-Group DifferencesPre-tx vs. 6mth FU, p<0.05G2 Within-Group Differences Pre-tx vs. 6mth, p<0.05G2 Within-Group Differences Post-tx vs. 6 mth FU, p<0.05 | NRNR |
| Bohus et al., 2013[23](#_ENREF_23) | G1: DBT-PTSDG2: TAU-WL | CAPSMean (SD)G1 Pre-tx: 87.92 (14.20)G1 Post-tx: 60.31(26.76) G1 18 week followup: 57.47 (25.66)G1 24 week followup: 58.50 (24.20)G2 Pre-tx: 82.63 (18.20)G2 Post-tx: 83.53 (16.50) G2 18 week followup: 79.74 (21.67)G2 24 week followup: 80.21 (19.21)Hedges’ g between group: 1.35Treatment X Time Interaction: -1.138 (0.195), p<0.001 | PDS Mean (SD)G1 Pre-tx: 2.22 (0.44)G1 Post-tx: 1.61 (0.64) G1 18 week followup: 1.53 (0.55)G1 24 week followup: 1.53 (0.65)G2 Pre-tx: 2.09 (0.45)G2 Post-tx: 2.09 (0.46) G2 18 week followup: 2.05 (0.47)G2 24 week followup: 2.00 (0.42)Hedges’ g between group: 1.00Treatment X Time Interaction: -0.021 (0.006), p<0.001 | Remission: NRLoss of Diagnosis at 12 weeks weeks (not meeting DSM-IV PTSD criteria any longer according to the CAPS) G1: 14 (38.9%)G2: 4 (10.5%)p=0.0018Borderline Personality Disorder SubgroupG1: 7 (41.2%)G2: 0 (0.0%)p=0.0058 |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Brady et al., 2000[66](#_ENREF_66) | G1: Sertraline25 to 200 mg/dayG2: Placebo | CAPS-2Mean change (SEM)G1: -33.0 (2.8)G2: -23.2 (2.9)Difference Between Mean Change (95% CI): 9.8 (1.8 to 17.7), p=0.02 | IESMean Change (SEM)G1: -16.2 (1.6)G2: -12.1 (1.6)Difference Between Mean Change (95% CI): 4.1 (-0.4 to 8.7), p=0.07DTS Mean Change (SEM)G1: -28.1 (2.8)G2: -16.1(2.8)G1 vs. G2 p=0.003 | NRNR |
| Brady et al., 2005[67](#_ENREF_67) | G1: Sertraline150 mg/dayG2: Placebo | CAPSANCOVAF (2, 68) = 2.68, p=0.08 | IESAuthors reported 'no significant difference between groups' (data NR) | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Bryant et al., 2003[41](#_ENREF_41) | G1: CBT, exposure based therapy (Prolonged Imaginal Exposure)G2: CBT-Mixed Prolonged Imaginal Exposure plus Cognitive RestructuringG3: Supportive Control | CAPS-IntensityMean (SD)G1 Pre-tx: 32.50 (8.71)G1 Post-tx: 19.15 (11.15)G1 6 mth FU: -20.70 (12.00)G2 Pre-tx: 32.70 (7.51)G2 Post-tx: 15.90 (13.36)G2 6 mth FU: 15.70 (14.79)G3 Pre-tx: 32.83 (8.01)G3 Post-tx: 28.00 (15.31)G3 6 mth FU: 30.28 (12.89)Post-tx, p<0.01 (main effects)FU, p<0.05 (main effects)CAPS-Frequency (CAPS-F)Mean (SD)G1 Pre-tx: 36.80 (9.82)G2 Post-tx: 20.55 (12.73)G1 6 mth FU: 23.25 (12.90)G2 Pre-tx: 36.00 (8.69)G2 Post-tx:17.20 (15.62)G2 6 mth FU: 17.00 (15.22)G3 Pre-tx: 38.33 (9.64)G3 Post-tx: 30.00 (16.42)G3 6 mth FU: 32.44 (13.57)Post-tx, p<0.01 (main effects)FU, p<0.05 (main effects) | IES-IntrusionsMean (SD)G1 Pre-tx: 23.85 (7.07)G1 Post-tx: 17.65 (7.34)G1 6 mth FU: 17.60 (9.88)G2 Pre-tx: 26.60 (7.02)G2 Post-tx:15.10 (12.86)G2 6 mth FU: 15.95 (12.18)G3 Pre-tx: 28.44 (6.60)G3 Post-tx: 15.10 (12.86)G3 6 mth FU: 25.44 (7.79)Post-tx, p<0.01 (main effects)FU, p<0.05 (main effects)IES-Avoidance Mean (SD)G1 Pre-tx: 26.40 (6.65)G1 Post-tx: 19.45 (13.48)G1 6 mth FU: 20.75 (12.66)G2 Pre-tx: 26.40 (6.65)G2 Post-tx: 16.15 (13.49)G2 6 mth FU: 14.95 (12.32)G3 Pre-tx: 26.17 (8.95)G3 Post-tx: 25.50 (9.54)G3 6 mth FU: 24.78 (9.55)Post-tx, p<0.01 (main effect)FU, p<0.05 (main effect) | NRNo longer met criteria for PTSD at Posttreatment G1: 50.0%G2: 65.0%G3: 33.0%p(G2/G3) <0.05No longer met criteria for PTSD at 6 month followupG1: 50.0%G2: 60.0%G3: 22.0%p(G1/G3) <0.07p(G2/G3) <0.05 |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Bryant et al., 2008[42](#_ENREF_42) | G1: CBT, exposure based (Imaginal Exposure)G2: CBT, exposure-based therapy (In vivo exposure)G3: CBT, exposure-based therapy (Imaginal Exposure/In vivo Exposure)G4: CBT-mixed Imaginal Exposure/In vivo Exposure/ cognitive restructuring | CAPSMean (SD)G1 Pre-tx: 73.29 (18.82)G1 Post-tx: 55.50 (33.83)G1 6 mth FU: 59.94 (32.36)G2 Pre-tx: 76.79 (15.53)G2 Post-tx: 55.96 (24.56)G2 6 mth FU: 59.32 (29.62)G3 Pre-tx: 76.06 (19.19)G3 Post-tx: 55.39 (37.45)G3 6 mth FU: 56.39 (35.87)G4 Pre-tx: 71.35 (17.28)G4 Post-tx: 29.86 (27.11)G4 6 mth FU: 32.86 (27.44)Post-tx, p<0.01 (main effect)6 mth FU, p<0.005 (main effect) | IES-Intrusions, Mean (SD)G1 Pre-tx: 24.48 (7.56)G1 Post-tx:19.94 (8.62)G1 6 mth FU: 20.87 (10.40) G2 Pre-tx: 24.21 (10.55)G2 Post-tx:17.25 (11.83)G2 6 mth FU: 19.21 (12.58)G3 Pre-tx: 27.58 (8.72)G3 Post-tx: 20.81 (13.17)G3 6 mth FU: 23.05 (12.14)G4 Pre-tx: 24.89 (8.01)G4 Post-tx: 14.07 (10.58)G4 6 mth FU: 13.35 (11.01)Post-tx, NS (main effect)6 month FU, p<0.05 (main effect)IES-Avoidance, Mean (SD)G1 Pre-tx: 29.10 (6.03)G1 Post-tx: 20.58 (11.52)G1 6 mth FU: 21.13 (10.56)G2 Pre-tx: 22.68 (10.52)G2 Post-tx:17.54 (12.29)G2 6 mth FU: 17.57 (10.85)G3 Pre-tx: 27.61 (8.50)G3 Post-tx: 21.81 (14.31)G3 6 mth FU: 25.16 (15.14)G4 Pre-tx: 23.71 (8.63)G4 Post-tx:13.14 (11.00)G4 6 mth FU: 13.18 (12.58)Post-tx, NS (main effect)6 month FU, p<0.05 (main effect) | NRNo PTSD at Posttreatment (Based on CAPS)G1: 37.0%G2: 35.0%G3: 41.0%G4: 65.0%p<0.10No PTSD at 6 month followup (Based on CAPS)G1: 25.0%G2: 31.0%G3: 37.0%G4: 69.0%p<0.01 |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Butterfield et al., 2001[82](#_ENREF_82)  | G1: Olanzapine5 to 20mg/dayG2: Placebo | SIP Mean (SD)G1 Pre-tx: 39.7 (9.7)G1 Post-tx: 19.2 (8.7)G2 Pre-tx: 45.9 (8.2)G2 Post-tx: 17.0 (17.5)TOP-8Mean (SD)G1 Pre-tx: 19.3 (4.2)G1 Post-tx: 12.6 (6.4)G2Baseline: 21.8 (3.3)G2 Post-tx: 10.5 (8.7)SPRINT - Mean (SD)G1 Pre-tx: 31.5 (5.7)G2 Post-tx: 17.9 (7.8)G2 Pre-tx: 34.8 (2.1)G2 Post-tx: 20.5 (11.1) | DTSMean (SD)G1 Pre-tx: 91.6 (25.4)G1 Post-tx: 57.4 (35.6)G2 Pre-tx: 95.8 (16.7)G2 Post-tx: 56.0 (36.6)G1 vs. G2, no group X time differences found | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Carey et al., 2012[81](#_ENREF_81) | G1: Olanzapine 5 to 10mgG2: Placebo | CAPSMean (SD)G1 Pre-tx: 79.4 (16)G1 Post-tx 4 week: 49.1 (27.2)G1 Post-tx 8 week: 33.6 (28.2)% CAPS score reduced: 57.7%G2 Pre-tx: 81.6 (11.3)G2 Post-tx 4 week: 73.21 (20.5)G1 G2 Post-tx 8 week: 62.3 (31.9)% CAPS score reduced: 23.7%Week 4 G1 vs G2, p = 0.014Week 8 G1 vs. G2, p = 0.018, Effect size, r = 0.43Response (>50% reduction in CAPS score)G1: 71%G2: 21% | DTSMean (SD)G1 Pre-tx: 75 (16.3)G1 Post-tx 4 week: 54.8 (27.7)G1 Post-tx 8 week 8: 37.9 (32)% CAPS score reduced: 51%G2 Pre-tx: 88.1 (22.5)G2 Post-tx 4 week: 86.2 (22.3)G1 Post-tx 8 week: 75.8 (34.5)% CAPS score reduced: 16%Week 4 G1 vs G2, p = 0.003Week 8 G1 vs. G2, p = 0.006, Effect size, r = 0.5 | CGI severity Mean (SD)G1 Pre-tx: 4.7 (0.8)G1 Post-tx 8 week: 2.9 (1.4)G2 Pre-tx: 5 (0.8)G1 Post-tx 8 week: 4.1 (1.3)Week 8 G1 vs. G2, p = 0.027, Effect size, r = 0.4Response (CGI improvement scale=much or very much improved)G1: 11 (78.6%) G2: 4 (28.6%)Loss of PTSD diagnosis NR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Carlson et al., 1998[46](#_ENREF_46)  | G1: EMDRG2: CBT, coping skills therapy (Biofeedback and general relaxation)G3: WL | CAPS - FrequencyMean (SD)G1 Pre-tx: 2.5 (0.5)G1 3 mth FU: 0.7 (0.6)G2 Pre-tx: 2.6 (0.5)G2 3 mth FU: 2.0 (0.7)G3 Pre-tx: 2.4 (0.6)NRGroup X Time, p<0.0004CAPS Total - Intensity:Mean(SD)G1 Pre-tx: 2.4 (0.7)G1 3 mth FU: 0.8 (0.7)G2 Pre-tx: 2.4 (0.5)G2 3 mth FU: 2.0 (0.5)G3 Pre-tx: 2.5 (0.6)NRGroup X Time, p<0.002CAPS Total - OverallMean Change (SD) at 9 monthsG1: 36.9 (28.6)G2: 67.8 (24.7)p<0.05 | IES TotalMean (SD)G1 Pre-tx: 52.5 (9.0)G1 Post-tx: 35.2 (22.0)G1 3 mth: 29.1 (22.0)G1 9 mth: 34.8 (28.0)G2 Pre-tx: 52.9 (9.3)G2 Post-tx: 44.5 (17.4)G2 3 mth: 45.7 (15.0)G2 9 mth: 47.0 (23.0)G3 Pre-tx: 52.8 (11.5)G3 Post-tx: 38.7 (16.2)Post-tx & 3 mth FU, Group X Time, p=NS9 month FU, p<0.24 (t-test)MISSMean (SD)G1 Pre-tx: 117.5 (14.3)G1 Post-tx: 92.8 (20.8)G1 3 mth: 92.4 (17.2)G1 9 mth: 97.8 (29.8)G2 Pre-tx: 119.4 (18.3)G2 Post-tx: 114.2 (17.5)G2 3 mth: 110.6 (18.6)G1 9 mth: 127.0 (12.4)G3 Pre-tx: 117.9 (17.6)G3 Post-tx: 112.9 (21.7) | NRPTSD diagnosis by CAPS at 3 months followup:G1: 77.8% (7 of 9) G2: 22.2% (2 of 9) |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Carlson et al., 1998[46](#_ENREF_46)(continued) |   |   | Group X Treatment, p<0.006 G1 vs. G3, p<0.05 (post-tx)G1 vs. G2, p<0.05 (post-tx & followup)3 month FU, p<0.05 (t-test)9 month FU, p<0.05 (t-test) |   |
| Chard et al., 2005[2](#_ENREF_2) | G1: CBT, cognitive processing therapyCPT-SAG2: WL  | CAPS-SXG1 Pre-tx: 65.46 (26.39)G1 Post-tx: 9.00 (11.04)G2 Pre-tx 68.30 (23.67)G2 Post-tx: 62.96 (30.68)p<0.001 (interaction) | MPSSMean (SD)G1 Pre-tx: 57.57 (22.85)G1 Post-tx: 7.54 (9.51)G2 Pre-tx: 57.52 (24.74)G2 Post-tx: 57.70 (27.47)p<0.001 (interaction) | NRNo longer met PTSD criteria based on CAPS-SX at PosttreatmentG1: 93% G2: 26%p<0.001 |
| Church et al., 2013[155](#_ENREF_155) | G1: EFT, Emotional Freedom Techniques (brief exposure therapy combining cognitive and somatic elements, on PTSD and psychological distress symptoms in veterans) G2: WL | NR | PCL-MMean (SE)G1 Pre-tx: 62.01 (2.1)G1 Post-tx: 39.41 (2.7)G2 Pre-tx: 62.71 (2.3)G2 Post-tx: 63.23 (2.0)Treatment X Time Interaction, <0.0001 | NRNR |
| Cloitre et al., 2002[37](#_ENREF_37) | G1: CBT, exposure-based therapy(STAIR)G2: WL | CAPSMean (SD)G1 Pre-tx:69 (16.3)G1 Post-tx: 31 (25.2)G2 Pre-tx:69 (16.6)G2 Post-tx:62 (22.7)p<.01 (interaction) | MPSS-SRMean (SD)G1 Pre-tx: 69 (16.6)G1 Post-tx: 29 (27.6) G2 Pre-tx:73 (18.6)G2 Post-tx:58 (28.6)p<0.01 (interaction)  | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Cloitre et al., 2010[148](#_ENREF_148) | G1: CBT-Mixed (STAIR) + PEG2: CBT-Mixed (STAIR) + Support (Skills Training) G3: Support (Skills Training) + PE | CAPSMean (SD)G1 Pre-tx:63.08 (18.29)G1 Post-tx: 32.70 (19.37)G1 3 mth FU:24.66 (18.47)G1 6 mth FU:20.44 (19.01)G2 Pre-tx: 64.34 (21.15)G2 Post-tx: 32.32 (23.04)G2 3 mth FU:31.88 (22.98)G2 6 mth FU:32.51 (22.69)G3 Pre-tx: 64.50 (15.86)G3 Post-tx: 39.72 (18.34)G3 3 mth FU: 39.71 (17.59)G3 6 mth FU: 28.56 (21.00)Group X TimeG1 vs. G3 at 3 mths, p=0.01No other contrasts significant  | PSS-SRMean (SD)G1 Pre-tx e:36.7 (12.87)G1 Post-tx: 14.0 (11.46)G1 3 mth FU:12.5 (11.41)G1 6 mth FU: 8.9 (9.83)G2 Pre-tx:39.9 (12.65)G2 Post-tx: 14.5 (12.79)G2 3 mth FU:17.3 (10.10)G2 6 mth FU: 13.7 (13.64)G3 Pre-tx: 38.2 (11.14)G3 Post-tx: 19.0 (9.83)G3 3 mth FU:21.4 (11.54)G3 6 mth FU: 20.5 (13.56)p=0.03(interaction)G1 pre vs. G1 post: p<0.001G1 pre vs. G1 3 mon: p<0.001G1 post to G1 6 mon: p<0.001 | PTSD-negative @ posttreatment G1: 61%G2: 47% G3: 33%p=0.11Persistence of PTSD-negative status (maintained their status through the 3-month and 6-months assessments)G1: 55% G2: 37% G3: 21%p=0.03G1 vs G3: p=0.01 OR (95% CI):4.23 (1.42–12.59)CAPS score <20 at posttreatmentG1: 27% G2: 24% G3: 6% p=0.04Remission Rate: (Pairwise analyses) G1 vs. G3: p=0.04 OR (95% CI): 5.67 (1.11–28.81).The rate of sustained PTSD full remission differed among the three groups G1: 24%, G2: 13% G3: 0% p=0.002 |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Coffey et al., 2016[140](#_ENREF_140) | G1: Modified PE+ Motivational enhancement therapy (met-ptsd), G2: PE as described in G1 without MET, relaxation prior to PE therapy.G3: HLS, relaxation prior to PE therapy | NR | IES-RMean (95% CI)G1 Pre-tx: 54.95 (49.51 to 60.39)G1 Post-tx: 20.49 (14.77 to 26.20) (p= 0.04)G1 3 month followup: 19.10(13.01 to 25.18) (p = 0.03)G1 6 month followup: 20.48 (14.53 to 26.42) (p < 0.05)G2 Pre-tx: 48.56 (43.43 to 53.68)G2 Post-tx: 16.20 (10.48 to 21.92) (p = 0.008)G2 3 month followup: 14.11(8.33 to 19.90) (p = 0.02)G2 6 month followup: 16.45 (10.85 to 22.06) (p = 0.13)G3 Pre-tx: 51.02 (45.65 to 56.60)G3 Post-tx: 27.40 (21.80 to 33.01)G3 3 month followup: 26.00 (20.15 to 31.85)G3 6 month followup: 26.50 (20.52 to 32.50)\*p-values in parentheses denote the treatment in comparison with G3Treatment x time interaction, post-tx: X2 = 7.25, p = 0.03 Difference in score reduction at post-tx, G1 vs. G2, p = 0.55Treatment X Time Interaction, followup: X2 = 0.32, p = 0.32, p = 0.99Cohen's d as compared with G3:G1 Post-tx: 0.36G2 Post-tx: 0.62G1 3 month: 0.36G2 3 month: 0.65G1 6 month: 0.31G2 6 month: 0.55 | NR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Connor et al., 1999[170](#_ENREF_170)Meltzer-Brody et al., 2000[171](#_ENREF_171) | G1: Fluoxetine10 to 60 mg/dayG2: Placebo | SIPWeek 12 difference (Baseline - Endpoint) (95% CI)G1 vs. G2 difference: 10.3 (3.7 to 16.9), p<0.005According to Meltzer-Brody paper, effect was significant for all 4 cluster scores (p<0.02) (intrusion, avoidance, numbing, hyperarousal)Duke Global Severity Rating for PTSD (Duke)Week 12 difference (Baseline - Endpoint) (95% CI)G1 vs. G2 Difference: 1.1 (0.6 to 1.6), p<0.0001 | DTSWeek 12 difference (Baseline - Endpoint) (95% CI)G1 vs. G2 Difference: 27.4 (11.2 to 43.5), p<0.005According to Meltzer-Brody paper, effect was significant (p<0.02) for all 4 cluster scores (intrusion, avoidance, numbing, hyperarousal) | NRNR |
| Cook et al., 2010[156](#_ENREF_156) | G1: CBT, exposure-based therapyG2: Psychoeducation | CAPSMean (SD)G1 Pre-tx: 81.34 (14.00)G1 Post-tx: 74.04 (20.36)G2 Pre-tx: 79.48 (15.27)G2 Post-tx:74.85 (19.52)p<0.001 (treatment effect, Wald) | PTSD Military Checklist Mean (SD)G1 Pre-tx: 62.73 (10.18)G1 1 mth:58.83 (13.56)G1 3 mth FU: 60.13 (12.16)G1 6 mth FU: 59.05 (11.78)G2 Baseline:65.06 (9.48) G2 1 mth:60.96 (11.43)G2 3 mth FU:61.13 (12.00)G2 6 mth FU: 59.64 (12.30)Interactions, NS | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Cottraux, 2008[31](#_ENREF_31) | G1: CBT-mixed (Exposure in imagination or in vivo and cognitive therapy)G2: Supportive Control | NR | PCLS <44 (criteria for loss of PTSD diagnosis) (Post-tx):G1: 33%G2: 14%Fisher's exact, p=0.12PCLS <35 (Post-tx)G1: 20%G2: 7%Fisher's exact, p=0.25PCLS, mean change (SD):Mean change in G1: -13.5 (13.2)Mean change in G2: -6.3 (12.9)Group Effect, p=0.044Interaction, NS | NRProportion without PTSD at posttest:G1+G2 > G3, chi-sq = 10.58, df = 2, p=0.01 |
| Davidson et al., 2001[68](#_ENREF_68) | G1: Sertraline50 to 200 mg/dayG2: Placebo | CAPS-2 Change from Baseline to Endpoint (SD)G1: -33.0 (2.4)G2: -26.2 (2.3)p=0.04 (t-test) | IES Change from Baseline to Endpoint (SD)G1: -19.2 (1.5)G2: -14.1 (1.5)p=0.02 (t-test)DTSChange from Baseline to Endpoint (SD)G1: -32.3 (2.8)G2: -20.0 (2.7)p=0.002 (t-test) | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Davidson et al., 2003[184](#_ENREF_184) | G1: Mirtazapine15 to 45 mg/dayG2: Placebo | SIPMean (SD)G1 Pre-tx:34.7 (7.0)G1 Post-tx:17.4 (4.0)G2 Pre-tx:38.4 (6.7)G2 Post-tx:32.9 (12.7)Between Tx effect size 1.06p=0.04 Treatment effect F=5.0; p=.04)SPRINTMean (SD)G1 Pre-tx:21.7 (6.0)G1 Post-tx:12.4 (8.8)G2 Pre-tx:25.0 (4.2)G2 Post-tx: 19.4 (8.2)Between Tx effect size 0.49 p=NS Treatment effect, F=1.7; p=.20 | DTSMean (SD)G1 Pre-tx: 74.8 (36.5)G1 Post-tx: 54.1 (40.0)Change: 20.7G2 Pre-tx: 93.8 (29.4)G2 Post-tx: 82.6 (27.7)Change: 11.2Treatment effect, p=0.20 | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Davidson et al., 2006[69](#_ENREF_69) | G1: Venlafaxine75 to 300mg/dayG2: Sertraline50 to 200mg/dayG3: Placebo | CAPS-SX17 Mean Within-group difference (95% CI):G1: -41.51 (-45.66 to -37.36) G2: -39.44 (-43.67 to - 35.21)G3: -34.17 (-38.33 to -30.01)Between group p-values based on pairwise comparisons from the analysis of covariance model using baseline adjusted valuesG1 vs. G3: 0.015G2 vs. G3: 0.081G1 vs. G2: 0.494  | DTSMean Within-group difference (95% CI):G1: -42.86 (-47.56 to -38.17) G2: -38.92 (-43.69 to -34.16)G3: -34.59 (-39.27 to -29.91)Between group p-values based on pairwise comparisons from the analysis of covariance model using baseline adjusted valuesG1 v G3: 0.015G2 v G3: 0.203G1 v G2: 0.248 | CAPS-SX17 total ≤ 20Scores reported in figure G1 vs. G3: p<0.05 at week 4 & 12G1 vs. G2: p<0.01 at week 4, <0.05 at week 6G1 vs. G3: p<0.001 at week 6NR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Davidson et al., 2006[73](#_ENREF_73) | G1: Venlafaxine37.5 to 300 mg/dayG2: Placebo | CAPS-SXMean (SD)G1 Pre-tx: 81.0 (14.62)G1 Post-tx: 29.2 (26.09)G2 Pre-tx: 82.9 (15.50)G2 Post-tx: 38.1 (29.11)Between Group Mean Difference-8.9, p=0.006 | NR | Remission Rates at 12 weeks (score ≤ 20 on CAPS-SX)G1: 42.9% (n=69/161)G2: 28.0% (n=47/168)p=0.005Remission Rates at 24 weeks (score ≤ 20 on CAPS-SX)G1: 50.9% (n=82/161)G2: 37.5% (n=63/168)p=0.01NR |
| Davidson et al., 2007[166](#_ENREF_166) | G1: Tiagabine4 to16mg/dayG2: Placebo | CAPS Change from baseline (SD)G1: 30.7 (25.1)G2: 30.2 (26.3)p=0.85DTS & TOP-8 NR, both NS | NR | G1: 16%G2: 14%p=0.88NR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Davis et al., 2008[164](#_ENREF_164) | G1: Divalproex1000 to 3000 mg/dayG2: Placebo | CAPSMean(SD)G1 Pre-tx: 75.2 (19.1)G1 Post-tx: 60.1 (24.1)G2 Pre-tx: 77.3 (15.3)G2 Post-tx: 60.8 (26.6)30% reduction in PTSD scores:G1: NRG2: NRDiff b/t groups, p>0.45G1 vs. G2, diff over time, p=NSTOP-8Mean(SD)G1 Pre-tx: 19.4 (5.3)G1 Post-tx: 15.4 (6.6)G2 Pre-tx: 19.7 (4.3)G2 Post-tx: 15.8 (6.5)G1 vs. G2, NS | DTSData Not PresentedG1 vs. G2, NS | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Ehlers et al., 2003[5](#_ENREF_5) | G1: CTG2: Self-help booklet based on principles of CBTG3: Repeated assessments | CAPS Frequency Mean (SD) G1 Pre-tx: 31.7 (9.5)G1 3 mth FU: 11.2(10.3)G1 9 mth FU: 10.2 (9.9)G2 Pre-tx: 32.6 (8.6)G2 3 mth FU: 22.9 (12.9) G2 9 mth FU: 21.4 (11.4)G3 Pre-tx: 32.8 (11.5)G3 3 mth FU: 25.6 (12.9) G3 9 mth FU: 21.1 (15.2)3 mth FUOverall: p<0.001 G1 vs. G2, p<0.001 G1 vs. G3, p<0.001 9 mth FUOverall: p<0.001 G1 vs. G2: p<0.001 G1 vs. G3: p=0.001 CAPS Intensity Mean (SD) G1 Pre-tx: 26.7 (7.4)G1 3 mth FU: 10.2 (9.4) G1 9 mth FU: 9.7 (9.5)G2 Pre-tx: 26.7 (7.4)G2 3 mth FU: 19.6 (9.0) 18.6 (10.1)G2 9 mth FU: G3: 22.4 (11.9)  | PDS Frequency Mean (SD) G1 Pre-tx: 30.2 (7.9)G1 3 mth FU: 8.3 (9.8)G1 9 mth FU: 8.7 (8.1)G2 Pre-tx: 30.9 (7.5)G2 3 mth FU: 19.9 (7.8) G2 9 mth FU: 20.0 (7.8)G3 Pre-tx: 31.1 (7.5)G3 3 mth FU: 22.6 (11.6)G3 9 mth FU: 19.4 (12.5)3 mth FU Overall: p<0.001 G1 vs. G2, p<0.001 G1 vs. G3, p<0.0019 mth FU Overall: p <0.001 G1 vs. G2, p<0.001 G1 vs. G3, p<0.001PDS DistressMean (SD) G1 Pre-tx: 31.6 (9.1)G1 3mth FU: 7.1 (10.3)G1 9 mth FU: 7.3 (8.6)G2 Pre-tx: 32.0 (7.2)G2 3 mth FU: 20.3 (8.2)G2 9 mth FU: 19.0 (8.8) | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Ehlers et al., 2003[5](#_ENREF_5)(continued) |   | G3 Pre-tx: 25.9 (10.4)G3 3 mth FU: 22.4 (11.9)G3 9 mth FU: 17.0 (13.8)3 mth FUOverall: p <0.001 G1 vs.G2: p<0.001 G1 vs. G3: p<0.0019 mth FUOverall, p=0.002 G1 vs.G2, p=0.001 G1 vs. G3, p=0.004 | G3 Pre-tx: 31.4 (8.4)G3 3 mth FU: 22.3 (12.2)G3 9 mth FU: 20.0 (14.1)3mth FUOverall: p<0.001 G1 vs. G2: p<0.001 G1 vs. G3: p<0.001 9 mth FUOverall: p <0.001 G1 vs. G2, <0.001 G1 vs. G3, <0.001 |   |
| Ehlers et al., 2005[8](#_ENREF_8) | G1: CBT-mixed Cognitive therapy including restructuring and exposureG2: WL | CAPS-Intensity Mean (SD)G1 Pre-tx: 36.5 (9.4)G1 Post-tx: 13.7 (13.4)G1 Post-tx FU adjusted: 10.4G1 6 mth FU: 15.5 (14.8)G2 Pre-tx: 29.0 (8.5)G2 Post-tx: 30.9 (9.6)G2 Post-tx adjusted: 34.2G1 vs. G2, p<0.005Changes in G1, p<0.005Changes in G2, NSCAPS-Frequency Mean (SD)G1 Pre-tx: 42.0 (8.5)G1 Post-tx: 16.0 (15.3)G1 Post-tx adjusted: 11.4G1 6 mth FU: 16.0 (14.4) | PDSMean (SD)G1 Pre-tx: 32.4 (6.5)G1 Post-txt: 10.3 (8.9)G1 6 mth FU: 12.4 (9.9)G2 Pre-tx: 31.2 (6.3)G2 Post-txt: 29.8 (8.4)G1 vs. G2, p<0.0005Changes in G1, p<0.0005Changes in G1, NS | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Ehlers et al., 2005[8](#_ENREF_8)(continued) |   | G2 Pre-tx: 31.6 (8.4)G2 Post-tx: 35.5 (11.4)G2 Post-tx adjusted: 40.2G1 vs. G2, p<0.005Changes in G1, p<0.005Changes in G2, NS |   |   |
| Ehlers et al., 2014[9](#_ENREF_9) | G1: Intensive CT (standard CT delivered over a much shorter period)G2: Standard CTG3: Supportive TherapyG4: WL | CAPS Mean (SD)G1 Pre-tx: 78.72 (19.80)G1 Post-tx: 32.22 (27.20)G1 Followup 1 (27 weeks): 35.56 (26.26)G1 Followup 2 (40 weeks):35.33(35.11)Within-group pre-post effect, d= 1.95G2 Pre-tx: 70.60 (13.45)G2 Post-tx: 26.97 (28.68)G2 Followup 1 (27 weeks): 20.86 (25.23)G2 Followup 2 (40 weeks): 20.96 (27.71)Within-group pre-post effect, d = 1.95G3 Pre-tx: 74.60 (15.39)G3 Post-tx: 47.88 (31.77)G3 Followup 1 (27 weeks):49.32(32.46)G3 Followup 2 (40 weeks): 49.04 (38.01)Within-group pre-post effect, d = 1.07 | PDS Mean (SD)G1 Pre-tx: 33.21 (7.66)G1 6 weeks: 14.85(8.92)G1 Post-tx:11.98 (9.60)G1 Followup 1 (27 weeks): 13.91 (11.63)G1 Followup 2 (40 weeks):13.03(13.99)Within-group pre-post effect, d= 2.45G2 Pre-tx: 32.44 (6.94)G2 6 weeks: 16.33 (11.58)G2 Post-tx: 9.39 (10.88)G2 Followup 1 (27 weeks): 10.15 (11.86)G2 Followup 2 (40 weeks): 9.63 (11.26)Within-group pre-post effect, d = 2.53G3 Pre-tx: 34.26 (7.40)G3 6 weeks: 23.30 (12.90)G3 Post-tx: 19.98 (13.67)G3 Followup 1 (27 weeks):18.93(12.98)G3 Followup 2 (40 weeks): 20.94 (15.40)Within-group pre-post effect, d = 1.30G4 Pre-tx: 32.46 (7.60)G4 6 weeks: 31.92 (6.84)G4 Post-tx: 29.24 (9.36)Within-group pre-post effect, d = 0.38 | Total Remission (no symptoms according to CAPS), n (%)G1 Post-tx:14 (46.7)G2 Post-tx:16 (51.6)G3 Post-tx:6 (20.0)G4 Post-tx: 1 (3.3)Greater remission in G1 and G2 vs. G3X2 = 22.19, p<0.001G1 Followup 1 (27 weeks):12 (40.0)G2 Followup 1 (27 weeks):21 (67.7)G3 Followup 1 (27 weeks):5 (16.7)Greater remission in G1 and G2 vs. G3X2 = 16.41, p<0.001G1 Followup 2 (40 weeks):16 (53.3)G2 Followup 2 (40 weeks):23 (74.2)G3 Followup 2 (40 weeks):8 (26.7)Greater remission in G1 and G2 vs. G3X2 = 13.84, p<0.01G1 NNT: 1.50 (95% 1.18 to 2.06)G2 NNT: 1.41 (95% 1.14 to 1.87)G3 NNT: 2.73 (95% 1.77 to 5.95) |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Ehlers et al., 2014[9](#_ENREF_9)(continued) |   | G4 Pre-tx: 69.95 (14.17)G4 Post-tx: 65.28 (20.64)Within-group pre-post effect, d = 0.26Comparison of Treatment with WaitlistTreatment by time Interactions, F=21.50, df=3, 135.35, p<0.002Between group effect sizesAdjusted Difference (95% CI)G1 vs. G4: -39.55 (26.60 to 52.51), p<0.001, d = 1.57G2 vs. G4: -38.80 (26.19 to 51.40), p<0.001, d= 1.55G1 vs. G3: -18.72(5.96 to 31.45), p <0.01, d=0.75G2 vs G3: -17.96 (5.31 to 30.62), p<0.01, d = 0.72Interaction between condition and Linear time effects: F=7.83, df=2, 154.13, p<0.001 | Comparison of Treatment with WaitlistTreatment by time Interactions, F=21.16, df=3, 106.56, p<0.002Between group effect sizesAdjusted Difference (95% CI)G1 vs. G4: 17.72 (12.54 to 22.90), p<0.001, d = 1.75G2 vs. G4:19.84 (14.71 to 24.97), p<0.001, d= 1.96G1 vs. G3: 7.37(2.19 to 12.55), p <0.01, d=0.73G2 vs G3: 17.96 (5.31 to 30.62), p<0.01, d = 0.72Interaction between condition and Linear time effects: F=4.42, df=2, 215.14, p = 0.01 | Loss of Diagnosis (CAPS, patient no longer met the minimum number of symptoms in each symptom cluster) required by DSM-IV,), n (%)G1 Post-tx:22 (73.3)G2 Post-tx:24 (77.4)G3 Post-tx:13 (43.3)G4 Post-tx: 2 (6.7)Greater loss of diagnosis in G1 and G2 vs. G3X2 = 38.92, p<0.001G1 Followup 1 (27 weeks):22 (73.3)G2 Followup 1 (27 weeks):23 (74.2)G3 Followup 1 (27 weeks):11 (36.7)Greater loss of diagnosis in G1 and G2 vs. G3X2 = 11.70, p<0.01G1 Followup 2 (40 weeks):20 (66.7)G2 Followup 2 (40 weeks):23 (74.2)G3 Followup 2 (40 weeks):12 (40.0)Greater loss of diagnosis in G1 and G2 vs. G3X2 = 8.18, p<0.05 |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Engel et al., 2015[26](#_ENREF_26) | G1: DESTRESS-PC, a nurse guided online CBT and stress inoculation training. G2: Optimized Usual Care, usual primary care PTSD treatment augmented with low intensity care management, feedback to the primary care provider, and training of the clinic providers in management of PTSD.  | NR | PCLMean (SD)G1 Pre-tx: 58.00 (9.95)G1 Post-tx (6 weeks, end of treatment): 50.72 (18.76)G1 Post-tx (12 weeks post randomization): 43.80 (18.33)G1 Post-tx (18 weeks post randomization): 44.58 (16.43)G2 Pre-tx: 54.48 (11.23)G2 Post-tx (6 weeks, end of treatment): 48.52 (13.97)G2 Post-tx (12 weeks post randomization): 47.36 (17.45)G2 Post-tx (18 weeks post randomization): 42.74 (14.42)Treatment by time interaction, F(3, 186) = 3.72, p = 0.12Largest treatment effect seen at 12 weeks post randomization (6 week followup), t(186)=2.44, p=.016 and diminishing by the 18-week post randomization (12 week followup) assessment (presented in figure)Effect Sizes6-week (end of treatment): 0.2312-week (6 weeks posttreatment): 0.4718-week (12 weeks posttreatment): 0.08 | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Fecteau et al., 1999[38](#_ENREF_38) | G1: CBT-mixed (Coping skills, exposure-therapy, and cognitive restructuring)G2: WL | CAPS-2 Mean (SD)G1 Pre-tx: 70.9 (16.2) G1 Post-tx: 37.5 (30.4) G2 Pre-tx: 77.3 (22.7) G2 Post-tx: 74.6 (24.7) Group effects, p<0.01  | IES-IMean (SD) G1 Pre-tx: 20.4 (8.7)G1 Post-tx: 8.3 (8.9)G2 Pre-tx: 24.8 (8.0) G2 Post-tx: 24.4 (8.4) Group Effects, p<0.01IES-AMean (SD) G1 Pre-tx: 24.7 (8.2) G1 Post-tx: 7.2 (11.4)G2 Pre-tx: 26.5 (10.5) G2 Post-tx: 24.4 (6.3)Group Effects, p<0.001 Followup for G1 OnlyIESMean (SD) G1 Pre-tx: 46.1 (14.7)G1 Post-tx: 15.5 (19.6)G1 3 mth FU: 13.0 (14.9)G1 6 mth FU: 8.3 (7.0)3 mth change, p<0.001 (n = 10)6 mth change, p<0.001 (n = 8) | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Foa et al., 1999[14](#_ENREF_14)Zoellner et al., 1999[134](#_ENREF_134) | G1: CBT, exposure-based therapy (PE)G2: CBT, coping skills therapy SITG3: CBT-mixed Combined treatment (PE and SIT)G4: WL | PSS-IMean (SD)G1 Pre-tx: 29.48 (9.94)G1 Post-tx: 11.70 (7.32)G1 3 mth FU: 11.84 (9.01)G1 6 mth FU: 11.16 (7.38)G1 12 mth FU: 10.69 (8.96)G2 Pre-tx: 29.42 (8.69)G2 Post-tx: 12.89 (8.96)G2 3 mth FU: 15.06 (13.33)G2 6 mth FU: 11.24 (11.86)G2 12 mth FU: 12.64 (14.71)G3 Pre-tx: 29.95 (6.97)G3 Post-tx: 13.55 (9.35)G3 3 mth FU:11.45 (9.03)G3 6 mth FU: 13.17 (10.98)G3 12 mth FU: 12.56 (12.25)G4 Pre-tx 32.93 (5.89)G4 Post-tx: 26.93 (8.47)Main Effects, p<0.01G1 vs. G4, p<0.001G2 vs. G4, p<0.05G3 vs. G4, p<0.05G1 vs. G2, p=0.14G1 vs. G3, p=0.11 | NR | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Foa et al., 2005[12](#_ENREF_12) | G1: CBT, exposure-based therapy(PE)G2: CBT-mixed (PE plus CR) G3: WL | PSS-IMean (SD)G1 Pre-tx: 34.0 (5.9)G1 Post-tx: 17.9 (14.5)G2 Pre-tx: 31.1 (8.1)G2 Post-tx: 16.8 (13.2)G3 Pre-tx: 33.3 (6.2)G3 Post-tx: 26.8 (9.6)Group X Time interaction, p<0.01G1 vs. G3 t-test, p<0.001 | NR | NRNR |
| Fonzo et al., 2017[137](#_ENREF_137)Fonzo et al., 2017[21](#_ENREF_21) | G1: PE G2: WL | CAPSMean (SD)G1 Pre-tx: 66.33 (15.17)G1 Post-tx: 29.60 (21.26)G2 Pre-tx: 71.37 (14.99)G2 Post-tx: 64.23 (21.77)Group X Time interaction, p<0.001 | PTSD Checklist for DSM-IV-Civilian VersionMean (SD)G1 Pre-tx: 56.16 (10.61)G1 Post-tx: 26.13 (7.08)G2 Pre-tx: 57.36 (12.04)G2 Post-tx: 49.00 (13.35)Group X Time interaction, p<0.001 | Remission (CAPS <20)G1:10G2:0Loss of PTSD DiagnosisG1: 21G2: 0 |
| Forbes et al., 2012[4](#_ENREF_4) | G1: CBT, cognitive processing therapyG2: TAU | CAPSMean (SD)G1 Pre-tx: 75.53 (16.35)G1 Post-tx: 48.03 (27.89)G1 3 month FU: 45.30 (28.15)G2 Pre-tx: 64.55 (19.46)G2 Post-tx: 57.73 (20.01)G2 3 month FU: 52.55 (18.93)Change over timePost-tx, p=0.002Post vs. 3 month FU, p=0.649 | PCLMean (SD)G1 Pre-tx: 61.63 (11.50)G1 Post-tx: 45.67 (16.66)G1 FU: 41.13 (17.51)G2 Pre-tx: 57.45 (12.55)G2 Post-tx:53.84 (11.11)G2 FU: 49.11 (11.00)Change over timePost-tx, p=0.007FU, p=0.943 | Loss of PTSD diagnosisG1:30G2: 10 |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Ford et al., 2011[59](#_ENREF_59) | G1: TARGETG2: PCTG3: WL | CAPSMean (SD)G1 Pre-tx: 62.3 (18.1)G1 Post-tx:38.7 (25.6)G2 Pre-tx: 61.9 (21.3)G2 Post-tx: 39.7 (21.4)G3 Pre-tx: 68.7 (17.0)G3 Post-tx: 62.5 (23.3)Group X Time Effect, p<0.001 | NR | Met Criteria for full remission at PosttreatmentG1: 21%G2: 15%G3: 0G1 vs. G2, p=0.45G1 vs, G3, p<0.001G2 vs. G3, p=0.007Met Criteria for full remission at 3 month FUG1:29%G2:19%Met Criteria for full remission at 6 month FUG1: 33%G2: 24.5%Approximately 60% in each group were in partial remission.Lost of PTSD diagnosisBaseline to Post-txG1:35%G2: 29%G3: 11% |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Ford et al., 20131[60](#_ENREF_60) | G1: TARGETG2: SGT  | CAPSMean (SD)G1 Pre-tx: 65.3 (18.0)G1 Post-tx: 50.0 (20.8)G2 Pre-tx: 63.1 (21.7)G2 Post-tx: 50.5 (24.3)Treatment X Time Interaction at post-tx, F= 0.3, NS, d = 0.13 | NR | Full remission (no full PTSD or partial PTSD at post-tx)G1: 4 (12%)G2: 8 (23%)Loss of PTSD Diagnosis (no longer meet criteria for full PTSD at post-tx)G1: 17 (43%)G2: 15 (44%) |
| Friedman et al., 2007[70](#_ENREF_70) | G1: Sertraline25 to 200 mg/dayG2: Placebo | CAPS-2Change at Endpoint (SE) G1: -13.1(3.0) G2: -15.4(3.1) Between Group Differences, NS | IES Change at Endpoint (SE) G1: -8.7(1.8) G2: -8.1(1.9)Between Group Differences, NSDTSChange at Endpoint (SE) G1: -11.4 (3.5) G2: -10.5 (3.5)Between Group Differences, NSMISS-Civilian Trauma VersionChange at Endpoint (SE) G1: -4.3 (1.7)G2: -2.8 (1.7) Between Group Differences, NS | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Galovski et al., 2012[6](#_ENREF_6) | G1: Modified CBT. Modifications include potential addition of stressor sessions and variable length of treatment. G2: Delayed treatment symptom monitoring | CAPS LSM (SE)G1 Pre-tx: 74.45 (2.42)G1 Post-tx: 26.96 (3.88)Difference: -47.5G2 Pre-tx: 77 (2.57)G2 Post-tx: 61.18 (3.98)Difference: -15.8(Hedge's g = 1.35)G1 vs. G2 Difference, -31.7, p <0.001 | PDS LSM (SD)G1 Pre-tx: 31.88 (1.25)G1 Post-tx: 11.63 (2.01)Difference: -20.3G2 Pre-tx: 35.28 (1.24)G2 Post-tx: 26.81 (2.07)Difference: -8.5(Hedge's g = .86)G1 vs. G2 Difference,-12.7, p <0.001 | NR NR |
| Gamito et al., 2010[141](#_ENREF_141) | G1: VRETG2: CBT, exposure-based therapy (Imaginal exposure)G3: WL | CAPSG1 Percentage variation: -8G2 Percentage variation: -1G3 Percentage variation: -6Effects, NS | IES-RG1 Percentage variation: -1G2 Percentage variation: 1G3 Percentage variation: 7 | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Gersons et al., 2000[51](#_ENREF_51)  | G1: Eclectic psychotherapy (Brief Eclectic Psychotherapy)G2: WL | NR | NR | Proportions by Treatment (%, p values)No PTSDPosttestG1: 91%G2: 50%p<0.013-month FollowupG1: 96%G2: 35%p<0.01NR |
| Haller et al., 2016[145](#_ENREF_145) | G1: Group ICBT for depression and SUD plus CPT-M (trauma-focused CPT modified to include substance use prevention) (individual)G2: Group ICBT for depression and SUD plus ICBT for depression and SUD (individual) | NR | PCLMean (SD)G1 Pre-tx: 51.46 (15.48)G1 Post-tx: 49.62 (14.04)G1 Post-tx (1 year followup): 48.33 (17.14)G2 Pre-tx: 49.88 (16.06)G2 Post-tx: 46.69 (15.74)G2 Post-tx (1 year followup): 39.47 (16.46)Scores were lower at the one year followup for participants in G2 compared to G1, F(1,71)= 5.58, p =.023. (based on only those participants who were assessed)Trajectory models that account for missing values did not indicate significant differences between groups over time. | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Hamner et al., 2003[83](#_ENREF_83)  | G1: Risperidone1 to 6 mg/dayG2: Placebo | CAPSMean (SD)G1 Pre-tx: 90.3 (23.0)G1 Post-tx: 81.3 (24.3)G2 Pre-tx: 89.1 (12.2)G2 Post-tx: 79.0 (21.0)Between-treatment changes, NS | NR | NRNR |
| Harned et al., 2014[144](#_ENREF_144) | G1: DBT plus DBT PE G2: DBT | PSS-IMean (SD)G1 Pre-tx: 32.8 (8.0)G1 Post-tx: 13.6 (13.2) G1 3 month followup: 16.7 (14.1)G2 Pre-tx: 30.1 (9.6)G2 Post-tx: 13.8 (9.3) G2 3 month followup: 18.4 (7.7)Between Group Effect size, Post: 0.0, followup: 0.1Treatment X time Interaction, F = 0.3 (3, 42), NS | NR | Loss of Diagnosis: Post-tx (ITT) (Defined as no longer meeting DSM-IV criteria for PTSD)G1: 58.3%G2:33.3%Remission at 3 month followupG1: 50%G2: 0 |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Hien et al., 2004[57](#_ENREF_57) | G1: Seeking SafetyG2: Relapse prevention condition (only substance abuse)G3: UC (Non-randomized Standard community Care) | CAPS Frequency and IntensityMean (SD)G1 Pre-tx: 72.17 (19.70)G1 Post-tx: 57.15 (22.33)G1 6 mth FU: 59.85 (21.12)G1 9 mth FU: 55.34 (20.85)G2 Pre-tx: 70.38 (16.84)G2 Post-tx: 51.21 (25.21)G2 6 mth FU: 52.65 (24.08)G2 9 mth FU: 47.82 (27.73)G3 Pre-tx: 73.88 (19.16)G3 Post-tx:68.00 (24.20)G3 6 mth FU:64.79 (23.81)G3 9 mth FU: 66.00 (23.99)CAPS Global SeverityMean (SD)G1 Pre-tx: 2.73 (0.63)G1 Post-tx: 2.14 (1.53)G1 6 mth FU:G1 9 mth FU: 1.79 (0.63)G2 Pre-tx: 2.41 (0.70)G2 Post-tx:1.75 (0.79)G2 6 mth FU: 1.62 (0.65)G2 9 mth FU: 1.40 (1.12)G3 Pre-tx: 2.82 (1.16)G3 Post-tx: 2.43 (1.09)G3 6 mth FU: 2.35 (0.70)G3 9 mth FU: 2.14 (1.07)Significance NR for CAPS | IES-RMean (SD)G1 Pre-tx: 47.49 (14.50)G1 Post-tx: 33.57 (14.92)G1 6 mth FU: 39.12 (17.23)G1 9 mth FU: 35.11 (16.82)G2 Pre-tx: 46.12 (10.57)G2 Post-tx: 28.90 (19.94)G2 6 mth FU: 36.38 (20.16)G2 9 mth FU: 29.67 (18.84)G3 Pre-tx: 51.52 (12.76)G3 Post-tx: 40.64 (20.43)G3 6 mth FU: 40.06 (17.62)G3 9 mth FU: 47.57 (13.21) | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Hien et al., 2009[157](#_ENREF_157)Hien et al., 2012[158](#_ENREF_158) | G1: Seeking SafetyG2: Psychoeducation | CAPS, ITT Analysis DataMean (SD)G1 Pre-tx: 61.6 (19.4)G1 Post-tx: 31.7 (23.4)G1 Average of FU: 24.3 (22.1)G2 Pre-tx: 64.2 (19.4)G2 Post-tx.: 32.7 (23.4)G2 Average of FU: 27.1 (23.4)Post-txG1 vs. G2, p<0.001 | PSS-SR, ITT Analysis DataMean (SD) G1 Pre-tx: 45.4 (15.3)G1 Post-tx: 32.7 (13.9)G1 Average Over FU: 30.0 (13.0)G2 Pre-tx: 45.6 (15.3)G2 Post-tx.: 33.8 (15.1)G2 Average Over FU: 32.0 (15.0)Post-txG1 vs. G2, p=0.5912-mth FU (Average Over)G1 vs. G2, p=0.97 | NRNR |
| Hinton et al., 2005[34](#_ENREF_34) | G1: CBT-mixed (Information on PTSD and Panic Disorder, relaxation techniques, culturally appropriate visualization, cognitive restructuring, exposure to anxiety-related sensations and trauma related memories, emotional-processing protocol, and cognitive flexibility)G2: WL | CAPSMean (SD)G1 Pre-tx: 74.85 (14.67)G1 2nd Assessment: 39.25 (19.92)G1 3rd Assessment: 41.30 (13.95)G1 FU Assessment: 44.56 (14.58)G2 Pre-tx: 75.91 (11.5)G2 2nd Assessment: 73.05 99.43)G2 3rd Assessment: 45.05 (8.72)G2 FU Assessment: 43.56 (10.22)Group Diffferences at 2nd Assessment, p<0.001Group Differences at 1st, 3rd, & 4th assessments, NS | NR | NRPercentage who no longer met PTSD criteria at assessment 2G1: 60% (n= 12)G2: 0%p<0.001 |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Hinton et al., 2009[151](#_ENREF_151) | G1: CBT-Mixed (Information on PTSD and Panic Disorder, muscle relaxation, guided imagery, mindfulness training, yoga-like stretching, cognitive restructuring, various exercises to teach emotional distancing and switching, and interoceptive exposure)G2: WL | CAPSMean (SD)G1 Pre-tx: 75.41 (13.47)G1 2nd Assessment: 46.83 (17.17)G1 3rd Assessment: 44.75 (14.85)G2 Pre-tx: 77.25 (11.47)G2 2nd Assessment: 74.25 (9.43)G2 3rd Assessment: 45.83 (8.45) Between group difference at 2nd assessment, p<0.01Between group differences at 3rd assessment, NS | NR | NRNR |
| Hinton et al., 2011[152](#_ENREF_152) | G1; CBT-mixed Culturally Adapted CBT (coping skills, cognitive "modification", mentions exposure) G2: Applied Muscle Relaxation  | NR | PTSD ChecklistMean (SD)G1 Pre-tx: 69.8 (6.5)G1 Post-tx: 39.1 (15.1)G1 FU: 36.4 (12.7)G2 Pre-tx: 71.1 (7.9)G2 Post-tx: 61.6 (13.2)G2 FU: 58.9 (14.7)Post-txG1 vs. G2, p<0.05 (t-test)FUG1 vs. G2, p<0.05 (t-test) | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Hogberg et al., 2007[48](#_ENREF_48) | G1; EMDRG2: WL | NR | IESMean (SD)Pre-txG1 Pre-tx: 39.3 (17.2)G1 Post-tx: 23.2 (17.4)G2 Pre-tx: 39.1 (12.6) G2 Post-tx: 34 (16.2)Within-group effect over time:G1: p<0.05G2: p<0.05Between group differences, NS | NR6 EMDR patients retained PTSD diagnosis, but denominator not givenG1:67% (8 of 12)G2: 11% (1 of 11)p=0.02 |
| Hollifield et al., 2007[32](#_ENREF_32) | G1: AcupunctureG2: CBT-mixed (Cognitive restructuring, behavior activation, and coping skills) G3: WL | NR | PSS-SRMean (SD)G1 Pre-tx: 31.33 (10.10)G1 Post-tx: 15.65 (13.95)G1 3 mth FU: 15.42 (12.54)G2 Pre-tx: 32.52 (6.63)G2 Post-tx: 20.02 (10.56)G2 3 mth FU: 16.68 (12.20)G3 Pre-tx: 30.79 (9.54)G3 Post-tx: 27.92 (12.33)G3 3 mth FU: 27.92 (12.33)RMANOVAG1 vs. G2, p=0.29 G1 vs. G3, p<0.01G2 vs. G3, p<0.01 | NRPSS-SR <16 at end of tx:G1: 68%G2: 43%G3: 19%PSS-SR <16 at 3-months:G1: 68%G2: 62% |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Ivarsson et al., 2014[24](#_ENREF_24) | G1: Internet based CBTG2: Delayed treatment attention control | NR | IES - (ITT)Mean (SD)G1 Pre-tx: 54.65 (13.16)G1 Post-tx: 30.96 (16.06)G2 Pre-tx: 54.87 (15.48)G2 Post-tx:49.19 (18.09)Differential average rates of changes between pre-and post treatment as a function of condition, -17.9 (95% CI, -25.2 to -10.6), t (58) = 4.9, P<0.001, d = 1.25 (95% CI, 0.65 to 1.80), favoring treatment PDS - (ITT)Mean (SD)G1 Pre-tx: 31.90 (6.52)G1 Post-tx: 17.32 (9.86)G2 Pre-tx: 29.84 (8.77)G2 Post-tx:25.04 (11.14)Treatment by time interaction =, -9.6 (95% CI, -13.8 to -5.3), t (54) = 4.5, P<0.001, d = 1.24 (95% CI, 0.64 to 1.81), favoring treatment | Remission: NRLoss of Diagnosis (no longer met criteria for PTSD based on CAPS):G1:81.5% (22)G2: 38.9 (14)Est = -1.55, SE = 0.62, p = 0.01, OR = 0.12, (95% CI, 0.06 to 0.71)Improvement based on CGIG1:63% (17)G2:13.8% (4)Est = 2.36, SE = 0.67, p = 0.001, OR = 10.63, (95% CI, 2.86 to 39.5) |
| Johnson et al., 2011[29](#_ENREF_29) | G1: CBT-mixed(Psychoeducation and CBT restructuring)G2: UC | CAPS Mean (SD)G1 Pre-tx: 53.34 (24.29)G1 Post-tx: 24.76 (18.47)G1 3 mth FU: 21.15 (24.79)G1 6 mth FU: 18.62 (18.84) G2 Pre-tx: 62.69 (25.38) G2 Post-tx: 42.38 (29.33) G2 3 mth FU: 31.27 (22.01) G2 6 mth FU: 26.56 (25.83) Time effect, *p<*0 .0001Treatment effect, p>0.05 | NR | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Kearney et al., 2013[159](#_ENREF_159) | G1: MBSR+TAUG2: TAU (VHA health system) | NA | PCL Mean (SD)G1 Pre-tx: 59.88 (11)G1 Post-tx: 52.45 (13)G1 4 month followup: 54.43 (15)G2 Pre-tx: 62.91 (11)G2 Post-tx: 58.5 (11)G2 4 Month followup: 60.16 (13)Post-tx, Between group: d = -.51 (95%, CI, -1.12 to 0.11)4 month followup: d = -.42 (95%, CI, -1.03 to 0.2)Clinically meaningful change (>=10 points) at PostTx:Mindfulness: 8 (36.4%)TAU: 5 (25%)Clinically meaningful change (>=10 points) at 4months:Mindfulness: 9 (39.1%)TAU: 5 (26.3%) | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Krakow et al., 2001[52](#_ENREF_52) | G1: IRT G2: WL | CAPSMean (SD) G1 Pre-tx: 81.88 (16.96)G1 Post-tx: 49.58 (23.96)Change: 32.3 (21.40)G1 Pre-tx: 79.62 (24.37)G2 Post-tx: 68.37 (27.26)Change: 11.25 (21.65)G1 vs. G2, p<0.001PSSMean (SD)G1 Pre-tx: 28.29 (10.37)G1 Post-tx: 17.19 (10.39)Change: 11.1 (11.06)G1 Pre-tx: 28.48 (11.73)G2 Post-tx: 25.26 (11.78)Change: 3.22 (9.02)G1 vs. G2, p<0.001 | NR | NRNR |
| Krystal et al., 2011[85](#_ENREF_85) | G1; Risperidone1 to 4 mg/dayG2: Placebo | CAPSMean Difference (95 % CI)2.73 (-0.74 to 6.20)p=0.12 | NR | % of veterans remitted based on CAPS at 24 weeks ╪G1: 4.9 G2: 4.0% of veterans with mild symptoms/ subdiagnostic based on CAPS at 24 weeks ╪G1: 14.6G2: 6.5 |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Kubany et al., 2003[35](#_ENREF_35) | G1: CBT, cognitive restructuringG2: WL | CAPS Mean (SD)G1 Pre-tx: 80.9 (20.7)G1 Post-tx: 10.1 (19.3)G1 3 mth FU: 7.9 (9.3)G2 Pre-tx: 79.1 (22.1)G2 Post-tx: 76.1 (25.2)G2 Post-therapy: 11.6 (13.6)G2 3 mth FU: 12.4 (13.8) G1 Post-tx change, p<0.05 G2 Post-tx change, NSG1 3 mth change, NSG2 Post-therapy, p<0.05G2 3 mth change, NS | NR | NRNo longer met diagnostic criteria for PTSD Based on CAPSG1: 94.0% G1: 0.0% |
| Kubany et al., 2004[28](#_ENREF_28) | G1: CBT-Mixed (Cognitive Trauma Therapy-Battered Women)G2: WL | CAPS (ITT Sample)Mean (SD)G1 Pre-tx:74.4 (19.9)G1 Post-tx: 33.3 (32.8)G2 Pre-tx: 78.0 (20.5)G2 Post-tx: 74.1 (21.9)Between group significance, NR | NR | NRLost of PTSD diagnosis based on completersG1: 91% G2: NR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Langkaas et al., 2017[142](#_ENREF_142)  | G1: PE G2: IRT  | PSS-IMean (SD)G1 Pre-tx: 34.9 (8.25)G1 Post-tx: 19.7 (13.92)G1 3 mth FU: 22.9 (15.74)G2 Pre-tx: 33.2 (6.91)G2 Post-tx: 21.9 (14.13)G2 12 mth FU: 23.5 (15.13)Treatment X Time Interaction, NS | NR | RecoveredG1 Post-tx: 48%G2 Post-tx: 50%G1 12 mth FU:39%G2 12 mth FU:38%ImprovedG1 Post-tx: 13%G2 Post-tx: 6%G1 12 mth FU:13%G2 12 mth FU: 9%Loss of Diagnosis NR |
| Li et al., 2017[172](#_ENREF_172) | G1; Sertraline 135 mg G2: Placebo | NR | IES-RChange at endpointG1: -24.3 (-32.1 to -14.3)G2:-18.1 (-25.7 to -11.8)Difference between groups: -6.4 to -2.6), p <0.01 | CGI-SeverityChange at endpointG1: -1.0 (-1.6 to -0.4)G2:-0.6 (-1.3 to -0.2)Difference between groups: -0.4 to -0.2), p <0.01Symptom reductionG1: 36 (100%)G2:25 (75%)Loss of PTSD diagnosis NR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Lindauer et al., 2005[50](#_ENREF_50) | G1: Eclectic psychotherapyBrief Eclectic Psychotherapy G2: WL | SI-PTSD Reexperiencing ScoreMean (SD)G1 Pre-tx: 3.4 (0.9)G1 Post-tx: 1.2 (1.5)G2 Pre-tx: 3.9 (0.8)G2 Post-tx: 3.1 (1.8)G1 vs. G2, p<0.05SI-PTSD Avoidance ScoreMean (SD)G1 Pre-tx: 3.9 (1.1.)G1 Post-tx: 1.6 (2.2)G2 Pre-tx: 3.5 (0.7)G2 Post-tx: 3.2 (1.7)G1 vs. G2, NSSI-PTSD Hyperarousal Mean (SD)G1 Pre-tx: 3.8 (0.9)G2 Post-tx: 1.3 (1.8)G2 Pre-tx: 3.8 (1.0)G2 Post-tx: 2.7 (1.5)G1 vs. G2, p<0.05 | NR | NRSI-PTSD scale used to diagnose PTSD, % improved at Post-txG1: 83.3%G2: 25%p<0.05 |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Litz et al., 2007[33](#_ENREF_33) | G1: CBT-mixed(Stress management skills, in vivo exposure, and relapse prevention)G2: Internet-delivered supportive counseling | PSS-IMean (SD) (Completer Group)G1 Pre-tx: 26.71 (9.02)G1 Post-tx: 14.86 (13.35)G1 3 mth FU: 13.20 (8.63)G1 6 mth FU: 8.67 (7.98)G2 Pre-tx: 29.16 (9.93)G2 Post-tx: 20.00 (11.50)G2 3 mth FU: 13.96 (8.63)G2 6 mth FU: 17.50 (10.40)ITT AnalysisPost-txTime effect, p<0.0013 mth FUG1 v.s G2, NSCompleter Analysis3 mth FUG1 vs. G2, NS6 mth FUGroup Effect, p =0.06 |   | NR% no longer meeting criteria for PTSD based on PSS-I <6ITT AnalysisPost-tx:G1:25%G2: 5%Likelihood ratio=3.89, p<0.053-mth F/U, p=NR6 mth F/UG1: 25%G2: 3%Likelihood ratio=8.35, p<0.01 |
| Maguen et al., 2017[25](#_ENREF_25) | G1: CBT, Impact of Killing (IOK) G2: WL | NR | PCLMean (SD)G1 Pre-tx: 48.6 (14.5)G1 Post-tx: 41.3 (11.2)Mean change: -7.33 (-14.71 to -0.05), t-test p = 0.0512G2 Pre-tx: 52.9 (11.3)G2 Post-tx: 50.7 (10.6)Mean change: -2.13 (-5.97 to -1.71), t-test p = 0.2534Between-group difference: -7.27 (-13.89 to -0.64), t-test p=0.033 | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Markowitz et al., 2015[132](#_ENREF_132)Markowitz et al., 2016[261](#_ENREF_261) | G1: PE G2: IPTG3: RT | CAPSMean (SD)G1 Pre-tx: 72.1 (18.2)G1 Post-tx: 37.5 (28.8)Change at Post-tx: 31.6, Effect size: 1.88G2 Pre-tx: 68.9 (16.2)G2 Post-tx: 39.8 (24.3)Change at Post-tx: 28.6, Effect size: 1.69G3 Pre-tx: 68.9 (16.4)G3 Post-tx: 46.5 (31.0)Change at Post-tx: 22.3, Effect size: 1.32Treatment X Time Interaction at post-tx, X2= 1.07, p = 0.343G1 vs. G3 Difference: -14.93, p = 0.010, Effect Size: -0.88G2 vs. G3 Difference: -9.47, p = 0.097, Effect Size: -0.56G2 vs. G1 Difference: 5.46, p = 0.323, Effect Size: 0.32 | Post Stress ScaleMean (SD)G1 Pre-tx: 77.7 (22.3)G1 Post-tx: 34.1 (26.4)Change at Post-tx: 36.1, Effect size: 1.81G2 Pre-tx: 74.3 (20.2)G2 Post-tx: 41.7 (26.1)Change at Post-tx: 32.1, Effect size: 1.61G3 Pre-tx: 83.2 (15.3)G3 Post-tx: 64.7 (27.4)Change at Post-tx: 14.1, Effect size: 0.71Treatment X Time Interaction at post-tx, X2= 4.67, p = 0.010G1 vs. G3 Difference: -30.75, p < 0.001, Effect Size: -1.55G2 vs. G3 Difference: -18.22, p = 0.008, Effect Size: -0.92G2 vs. G1 Difference: 12.54, p = 0.053, Effect Size: 0.63 | Remission (CAPS score <20)G1: 26%G2: 23%G3: 22 %NR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Marks et al., 1998[122](#_ENREF_122)Lovell et al., 2001[123](#_ENREF_123) | G1: CBT, exposure-based therapy(PE)G2: CBT, cognitive restructuringG3: CBT-mixed Exposure (Combined with CR)G4: Relaxation | Marks et al., 1998[122](#_ENREF_122)CAPS-2, Mean Change Score at Post-tx (95% CI)G1: 30 (19 to 42) G2: 36 (26 to 45)G3: 38 (26 to 50)G4: 14 (4 to 25)Additional results presented in graphsCAPSMean change in G1 + G2 + G3 vs. G4Post, p=0.0051 mth FU, p=0.013 mth FU, p=0.005Lovell et al., 2001[123](#_ENREF_123)CAPS, Re-experiencing subscaleMean (SD)G1 Pre-tx: 13.3 (3.9)G1 Post-tx: 6.8 (7.5)G2 Pre-tx: 14.9 (5.0)G2 Post-tx: 7.8 (4.9)G3 Pre-tx: 15.1 (6.4)G3 Post-tx: 6.8 (7.2)G4 Pre-tx: 11.6 (6.1)G4 Post-tx: 9.7 (7.4)Post-txG1 + G2 +G3 vs. G4, p<0.02FollowupsG1 + G2 +G3 vs. G4, NS | IES (first 11 weeks)Mean Change Score (95% CI)G1: 28 (19 to 37)G2: 25 (15 to 34)G3: 35 (24 to 49)G4: 13 (5 to 19)Additional results presented in graphsIESMean change in G1 + G2 + G3 vs. G4Post, p=0.0081 mth FU, p=0.083 mth FU, p=0.05 | NRPTSD Criteria not meet by CAPSG1: 75%G2: 65%G3: 63%G4: 55% |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Marks et al., 1998[122](#_ENREF_122)Lovell et al., 2001[123](#_ENREF_123)cont’d |   | CAPS, Advoidance/numbing subscaleMean (SD)G1 Pre-tx: 23.4 (8.3)G1 Post-tx: 11.5 (13.1)G2 Pre-tx: 30.7 (7.6)G2 Post-tx: 15.2 (11.0)G3 Pre-tx: 29.8 (9.3)G3 Post-tx: 11.9 (11.9)G4 Pre-tx: 23.0 (9.1)G4 Post-tx: 17.1 (8.9)Post-txG1 + G2 +G3 vs. G4, p<0.0041 month FUG1 + G2 +G3 vs. G4, p<0.023 month FUG1 + G2 +G3 vs. G4, p<0.01CAPS, Increased arousal subscaleMean (SD)G1 Pre-tx: 25.2 (8.5)G1 Post-tx: 13.2 (11.1)G2 Pre-tx: 29.1 (8.8)G2 Post-tx: 16.5 (10.0)G3 Pre-tx: 28.6 (7.7)G3 Post-tx: 16.6 (11.7) |   |   |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Marks et al., 1998[122](#_ENREF_122)Lovell et al., 2001[123](#_ENREF_123)cont’d |   | G4 Pre-tx: 23.7 (7.6)G4 Post-tx: 17.0 (10.5)Post-txG1 + G2 +G3 vs. G4, NS |   |   |
| Marks et al., 1998[122](#_ENREF_122)Lovell et al., 2001[123](#_ENREF_123)cont’d |   | FollowupsG1 + G2 +G3 vs. G4, NSCAPS, Associated features subscaleMean (SD)G1 Pre-tx: 16.7 (9.0)G1 Post-tx: 8.1 (9.7)G2 Pre-tx: 22.6 (10.2)G2 Post-tx: 10.3 (8.8)G3 Pre-tx: 20.8 (10.8)G3 Post-tx: 11.0 (11.0)G4 Pre-tx: 15.2 (8.0)G4 Post-tx: 12.0 (11.0)Post-txG1 + G2 +G3 vs. G4, p<0.04FollowupsG1 + G2 +G3 vs. G4, NS |   |   |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Marshall et al., 2001[64](#_ENREF_64) | G1: Paroxetine20 mg/day G2: Paroxetine40 mg/dayG3: Placebo | CAPS-2Adjusted Mean Differences (95% CI)G1 vs. G3-14.3 (-19.7 to -8.8)p<0.001G2 vs. G3-12.2 (-17.7 to -6.6)p<0.001TOP-8Adjusted Mean Differences (95% CI)G1 vs. G3-3.4 (-5.1 to -1.8)p<0.001G2 vs. G3-2.9 (-4.5 to -1.3)p<0.001 | DTS Adjusted Mean Differences (95% CI)G1 vs. G3-12.2 (-18.1 to -6.3)p<0.001G2 vs. G3-10.9 (-16.9 to -4.9)p<0.001 | NRNR |
| Martenyi et al., 2002[61](#_ENREF_61)Martenyi et al., 2006[173](#_ENREF_173) | G1: Fluoxetine20 to 80 mg/dayG2: Placebo | CAPSChanges from Pre-tx to Post-txLeast Square Means (SD), p-valueG1: -34.6 (28.1)G2: -26.8 (26.1)p=0.021TOP-8 Changes from Pre-tx to Post-txLeast Square Means, p-valueG1: -10.3G2: -8.0p=0.006 | DTSChanges from Pre-tx to Post-txLeast Square Means (SE), p-valueG1: -33.8 (2.25)G2: -27.3 (3.66)p=0.117 | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Martenyi et al., 2007[62](#_ENREF_62) | G1: Fluoxetine20 mg/dayG2: Fluoxetine40 mg/dayG3: Placebo | CAPS Mean change from baseline (SD) ITT AnalysisG1: -42.9 (23.1)G2: -42.8 (27.9)G3: -36.6 (25.7) Overall p-value= 0.15TOP-8 Mean change from baseline (SE)Completer analysisG1: -10.59 (0.58)G2: -10.25 (0.60)G3: -10.59 (0.81)Overall p-value= 0.907 | NR | NRLoss of PTSD Diagnosis G1: 40.5% G2: 38.8%G3: 37.5 |
| Maxwell et al., 2016[124](#_ENREF_124) | G1: MESTG2: CPT | NR | MPSS-SRMean (SD)G1 Pre-tx:63.50 (18.37)G1 Post-tx:54.13 (24.87)G1 3 mth FU: 33.5 (25.39)G2 Pre-tx:49.00 (26.60)G2 Post-tx:38.13 (15.06)G2 3 mth FU: 25.13 (23.31)Cohen’s d = .50 | NRNR |
| McDonagh et al., 2005[39](#_ENREF_39) | G1: CBT-mixed (Exposure and cognitive restructuring therapy)G2: PCTG3: WL | CAPSMean (SD)G1 Pre-tx: 69.9 (16.8)G1 Post-tx: 53.1 (28.8)G2 Pre-tx: 67.7 (14.6)G2 Post-tx: 47.2 (22.4)G3 Pre-tx: 72.0 (17.6)G3 Post-tx: 65.5 (18.6)Group X Time, p<0.10 | NR | NRNo longer met criteria for PTSD (CAPS)G1: 27.6%G2: 31.8%G3: 17.4% |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| McGovern et al., 2015[27](#_ENREF_27) | G1: ICBT plus SC, manual-guided therapy focused on PTSD andsubstance use. G2: IAC plus SC, (focused exclusively on substance use and recovery) (arm not eligible)G3: SC (intensive out-patient program services) | CAPSMean (SD)G1 Pre-tx: 76.71 (18.13)G1 Post-tx (6 month): 46.81(24.81)G3 Pre-tx: 76.51 (20.83)G3 Post-tx (6 month):52.60(26.46)NS difference between G1 and G3Parameter Estimate and CIsG1 vs. G3, -4.95 (95% CI, -13.65 to 3.74)Effect sizeG1 vs. G3: -0.24 | NR | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Mills et al., 2012[20](#_ENREF_20) | G1: COPE, a modification of Concurrent Treatment of PTSD and Cocaine Dependence. (motivational enhancement, psychoeducation, in vivo exposure, imaginal exposure, and cognitive therapy)G2: TAU.  | CAPSMean (95% CI)G1 Pre-tx: 91.13 (87.03 to, 95.23)G1 Post-tx: 52.90 (43.72 to 62.06)Mean difference: -38.24 (-47.93, -28.54), p < 0.001G2 Pre-tx: 89.83 (84.70 to 94.06)G2 Post-tx: 67.23 (59.21 to 75.25)Mean difference: -22.14 (-30.33 to -13.95), p < 0.001Between group difference Pre-tx to FU: -16.09 (-29.00 to -3.19), p = 0.02Treatment X Time Interaction: X2 = 5.38, p = 0.02 | NR | NRNR |
| Monnelly et al., 2003[167](#_ENREF_167) | G1: Risperidone0.5 to 2.0mg/dayG2: Placebo | NR | PCL-MMedian Change ScoresG1: -10.0 G2: -0.5p=0.02 | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Monson et al., 2006[1](#_ENREF_1) | G1: CBT, CPTG2: WL | CAPSMean (SE)G1 Pre-tx: 76.73 (2.6)G1 Post-tx: 52.14 (3.9)G1 1 mth FU: 58.13 (4.5)G2 Pre-tx: 79.10 (3.5)G2 Post-tx: 76.03 (3.7)G1 1 mth FU: 74.37 (4.3)Group X Time, p<0.01 | NR | NRDid Not Meet Diagnostic Criteria for PTSD at Post-treatmentG1: 40% (n=12)G2: 3% (n=1)p<0.001Did Not Meet Diagnostic Criteria for PTSD at 1-monthG1: 30% (n= 9) G2: 3% (n=1)p=0.01 |
| Monson et al., 2012[22](#_ENREF_22) | G1: CBCT, manualized cognitive-behavioral conjoint therapy for PTSD delivered in a couple therapy format G2: WL | CAPSMean (95% CI)G1 Pre-tx: 68.87 (62.12 to 75.61)G1 Post-tx: 33.45 (22.03 to 44.87)Change: -35.42 (-47.84 to -23.00)Effect size Hedge g: 1.82 (1.00 to 2.62)G2 Pre-tx: 73.03 (66.29 to 79.76)G2 Post-tx: 60.82 (49.87 to 71.78)Change: -12.20 (-21.51 to -2.89)Effect size Hedge g: 0.57 (0.12 to 1.00)Change Difference Mean Between Groups: -23.21 (-37.87 to -8.55) | PTSD ChecklistMean (95% CI)G1 Pre-tx: 49.92 (45.12 to 54.71)G1 Post-tx: 30.38 (22.81 to 37.96)Change: -19.53 (-27.30 to -11.77)Effect size Hedge g: 1.61 (0.83 to 2.37)G2 Pre-tx: 57.89 (53.10 to 62.67)G2 Post-tx: 46.80 (36.61 to 53.99)Change: -11.09 (-18.34 to -3.85)Effect size Hedge g: 0.71 (0.21 to 1.20)Change Difference Mean Between Groups: -8.44 (-18.71 to -1.83)Effect size Hedge g: 0.60 (-0.10 to 1.29) | NRLoss of PTSD Diagnosis at posttreatment (not meeting DSM-IV-TR symptom criteria and a total score lower than45 on the CAPS)G1: 13 (81%)G2: 4 (21%) |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Monson et al., 2012[22](#_ENREF_22) (continued) |   | Effect size Hedge g: 1.13 (0.40 to 1.85)Treatment X Time Interaction, t (37, 5) = -3.09, p = 0.004 |   |   |
| Moradi et al., 2014[160](#_ENREF_160) | G1: MEmory Specificity Training (MEST) G2: Control, no additional contact | NR | IES-RTreatment X Time Interaction, F(2, 44) = 176.48, p < 0.001, η2 = 0.89 | NRNR |
| Morath et al., 2014[55](#_ENREF_55) | G1: NETG2: WL | CAPSMean (SD)G1 Pre-tx: 92.41 (14.95)G1 Post-tx: 58.65 (24.93)G1 1 year post-tx:51.88 (24.52)G2 Pre-tx: 76.88 (15.95)G2 Post-tx: 74.59 (20.42)Treatment X Time Interaction at post-tx, F (1, 32) = 16.90, p = 0.0003 | NR | NRNR |
| Mueser et al., 2008[7](#_ENREF_7) | G1: CBT-mixed (CBT for PTSD) G2: UC | CAPS Mean (SD)G1 Pre-tx: 74.46 (17.56)G1 Post-tx: 55.53 (27.92)G1 3 mth FU: 55.10 (25.96)G1 6 mth FU: 57.48 (25.34)G2 Pre-tx: 76.15 (17.07)G2 Post-tx: 67.78 (26.84)G2 3 mth FU: 64.80 (28.25)G2 6 mth FU: 70.90 (24.15)Group effect, p=0.005 | NR | NRLoss of PTSD DiagnosisCAPS Dx, n(%)G1 Pre-tx: 54 (100.0)G1 Post-tx: 21 (67.7)G1 3 mth FU: 19 (63.3)G1 6 mth FU: 24 (72.7)G2 Pre-tx: 54 (100.0)G2 Post-tx: 21 (77.8)G2 3 mth: 27 (77.1)G2 6 mth: 17 (85.0)Group effect, p=0.63, |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Nacasch et al., 2011[15](#_ENREF_15) | G1: CBT, exposure-based therapy (Prolonged exposure therapy)G2: TAU | PSS-IMean (SD)G1 Pre-tx: 37.1 (3.8)G1 Post-tx: 18.9 (9.1)G1 FU: 16.3 (10.4)G2 Pre-tx: 36.8 (6.2)G2 Post-tx: 35.0 (8.9)G2 FU: 35.4 (7.6)Post-txTreatment X Time, p<0.00112 month FUTreatment X Time (Pre to FU), p<0.001Treatment X Time (Post to FU), NS | NR | NRNR |
| Neuner et al., 2004[161](#_ENREF_161) | G1: CBT, exposure-based therapy (NET)G2: Supportive CounselingG3: Psycho-education About the nature and prevalence of PTSD  | Composite International Diagnostic Interview-PTSDMean (SD)G1 Pre-tx: 13.4 (2.1)G1 1 year FU: 8.9 (2.7)G2 Pre-tx: 13.9 (2.3)G2 1 year FU: 12.6 (3.2)G3 Pre-tx: 14.2 (2.9)G3 1 year FU: 13.4 (3.3)1 year Group X TimeG1 vs. G2, p=0.01G1 vs. G3, p=0.01 | PDSMean (SD)G1 Pre-tx: 25.2 (7.4)G1 Post-tx: 19.1 (11.7)G1 4 mth FU: 24.5 (7.8)G1 1 year FU: 16.0 (5.1)G2 Pre-tx: 22.0 (8.0)G2 Post-tx:19.8 (10.9)G2 4 mth FU: 22.8 (23.1)G2 1 year FU: 23.1 (7.7)G3 Pre-tx: 19.5 (8.0)G3 Post-tx: 21.2 (9.4)G4 Post-tx: 27.7 (6.6)G3 1 year FU: 23.9 (7.0)1 year Group X TimeG1 vs. G2, p=0.01G1 vs. G3, p=0.01 | NRPercentage of Patients Without a PTSD Diagnosis at 1 year followupG1: 71.0%G2: 21.0%G3: 20.0% |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Neuner et al., 2008[54](#_ENREF_54) | G1: CBT, exposure based (NET)G2: Flexible Trauma Counseling G3: No-treatment monitoring group | PDSMean (SD)G1 Pre-tx: 25.9 (13.2)G1 Post-tx: 5.4 (6.6)G1 6 mth FU: 6.1 (6.8)G2 Pre-tx: 26.7 (12.5)G2 Post-tx: 5.3 (5.7)G2 6 mth FU: 5.0 (6.6)G3 Pre-tx: 21.3 (10.6)G3 Post-tx: NRG3 6 mth FU: 10.1 (8.1)G1 vs. G2 ComparisonsGroup X Time at Post-tx, p=0.87Treatment Groups vs. ControlTreatment X Time, p=0.01 | NR | NRNo longer fulfilled criteria for PTSD at 9 months. G1: 69.85%G2: 65.2%G3: 36.8% |
| Neuner et al., 2010[53](#_ENREF_53) | G1: CBT, exposure based (NET)G2: UC | PDSMean(SD)G1 Pre-tx: 38.9 (6.4)G1 Post-tx: 26.0 (9.2)G2 Pre-tx: 36.9 (8.0)G2 Post-tx: 34.1 (6.1)Group X Time, p=0.01 | NR | NRLoss of PTSD DiagnosisG1: 6.25%G2: 0% |
| Nijdam et al., 2012[154](#_ENREF_154) | G1: Eclectic psychotherapyG2: EMDR | SI-PTSDMean Difference at 1st Post (95% CI)10.80 (6.37 to 15.23)p<0.001Mean Difference at 2nd Post (95% CI)2.41 (-2.10 to 6.92)p=0.29 | NR |   |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Panahi et al., 2011[71](#_ENREF_71) | G1: Sertraline50 to 200 mg/dayG2: Placebo | NR | NR |   |
| Petrakis et al., 2012[185](#_ENREF_185), [240](#_ENREF_240) | G1: Paroxetine (40 mg/day)+ Naltrexone (50 mg/day) Participants who could not tolerate the highest dose were brought to lower doses.G2: Paroxetine (40 mg/day) +PlaceboParticipants who could not tolerate the highest dose were brought to lower doses.G3: Desipramine (200 mg/day) + Naltrexone (50 mg/day) Participants who could not tolerate the highest dose were brought to lower doses.G4: Desipramine (200 mg/day + PlaceboParticipants who could not tolerate the highest dose were brought to lower doses. | CAPSMean(SE)G1 Pre-tx: 73.54 (5.007)G1 Post-tx: 40.024 (5.53)G2 Pre-tx: 69.810 (5.166)G2 Post-tx: 36.591 (5.570)G3 Pre-tx: 62.500 (5.047)G3 Post-tx: 26.751 (5.353)G4 Pre-tx: 77.833 (4.832)G4 Post-tx: 41.392 (4.949)Time effect, p<0.00Group X Time, NS | NR | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Polusny et al., 2015[136](#_ENREF_136) | G1: 8 weekly group sessions and a daylong retreat. 1st session was an orientation that included rational and psychoeducation. 7 sessions of mindfulness therapy and 1 6.5 hour retreat. G2: Group Sessions  | CAPSMean (95% CI)G1 Pre-tx: 69.9 (51.0 to 61.5)G1 Post-tx: 56.3 (51.0 to 61.5)G1 2 month followup: 49.8 (44.3 to 55.3)G2 Pre-tx: 62.5 (57.6 to 67.4)G2 Post-tx: 51.7 (46.5 to 56.8) G2 2 month followup: 50.6 (45.4 to 55.8)Between group mean difference at post-tx: -2.35, p=0.37Between group mean difference at 2 month followup: -7.89 p= 0.004Treatment x time interaction at 2 months: F = 4.75, P =0.03Clinically significant improvement: G1 Post-tx: 33 (63.5%)G2 Post-tx: 28 (49.1%)G1 2 month followup: 30 (66.7%)G2 2 month followup: 30 (54.5%)Between group mean difference at Post-tx: 14.3%, p = 0.13Between group mean difference at 2 month followup: 42.1%, p=0.22 | PCLMean (95% CI)G1 Pre-tx: 63.6 (60.6 to 66.7)G1 Post-tx: 55.7 (52.6 to 58.9)G1 2 month followup: 55.4 (51.2 to 57.6)G1 Pre-tx: 58.8 (55.7 to 61.8)G2 Post-tx: 55.8 (52.7 to 58.9)G2 2 month followup: 56.0 (52.9 to 59.0)Between group mean difference at posttreatment: -4.95, p =0.002Between group mean difference at 2 month followup: -6.44, t = 4.08, P <0.001Group x time interaction at 2 months: F= 8.78, P=0.004Clinically significant improvement: G1 Post-tx: 19 (36.5%)G2 Post-tx: 13 (22.8%)G1 2 month followup: 23 (48.9%)G2 2 month followup: 16 (28.1%)Between group mean difference at Post-tx: 13.7%, p =0.12Between group mean difference at 2 month followup: 20.9%, p= 0.03 | Loss of CAPS diagnosis, n (%)G1 Post-tx: 22 (42.3%)G1 2 month followup: 24 (53.3%)G2 Post-tx: 25 (43.9%)G2 2 month followup: 26 (47.3%)Post-tx, Between group mean difference: 1.6%, chi-sq = .03, p=0.872 month followup, Between group mean difference: 6%, chi-sq = .36, P=0.55Remission NR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Raskind et al., 2003[74](#_ENREF_74) | G1: Prazosin2 to 10 mg/dayG2: Placebo | CAPS G1 Pre-tx:79.1 (17.0)G1 Post-tx: 57.3 (32.3)G2 Pre-tx: 83.6 (17.6)G2 Post-tx: 86.5 (30.0)G1 vs. G2 Change, p<0.01 | NR | NRNR |
| Raskind et al., 2007[75](#_ENREF_75) | G1: Prazosin2 to 15 mg at bedtimeG2: Placebo | CAPSMeans (SD)G1 Pre-tx: 76.0 (22)G1 Post-tx: 63.0 (20.0)G2 Pre-tx: 78.0 (18.0)G2 Post-tx: 71.0 (22.0)G1 vs. G2 Change, NS | NR | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Raskind et al., 2013[76](#_ENREF_76) | G1: Prazosin 1 to 5 mg/day morning dose, 1 to 20mg/day bedtime doseG2: Placebo  | CAPSAdjusted Means (95% CI)G1 Pre-tx: 77.3 (69.1 to 85.5)G1 Post-tx: 52.2 (43.8 to 60.5)Mean Change: 25.1 (SE = 3.4)G2 Pre-tx: 85.7 (78.0 to 93.3)G2 Post-tx: 71.9 (63.9 to 79.8)Mean Change: 13.8 (SE = 3.3)Between Group Difference in Change from Baseline: 11.3 (2.0 to 20.7), t = 2.39, p = 0.02Subgroup Analysis Week-by-Treatment group-by-SSRI use Interaction for CAPS, p = 0.0007Change in CAPS between baseline and week 15 (G1 only) PrazosinNot Receiving SSRI: 30.1 point decrease (SE =3.8)Receiving SSRI: 9.6 point decrease (SE=6.8) | NR | CGIAdjusted Means (95% CI)G1 Post-tx: 2.3 (1.8 to 2.7)G2 Post-tx: 3.2 (2.8 to 3.6)Between Group Difference in Change from Baseline: 0.9 (0.3 to 1.5), t = 3.13, p = 0.003Treatment by SSRI use Interaction for CGI change NSResponders (CGI change item markedly or moderately improved=scores of 1 or 2)G1: 64% (44 to 79)G2: 27% (14 to 45)Difference in % responders, p<,0.001, OR = 4.8, (1.9 to 12.2)Full Remission (CAPS <20)G1: 3G2: 0Loss of PTSD diagnosis NR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Reger et al., 2016[18](#_ENREF_18) | G1: VREG2: PEG3: WL (minimum attention) | CAPS (week)Mean (SD)G1 Pre-tx: 80.44 (16.23)G1 Post-tx: 57.07 (32.32)G1 12 week: 56.64 (31.50)G1 26 week: 53.50 (28.07)G2 Pre-tx: 78.28 (16.35)G2 Post-tx: 44.28 (33.73)G2 12 week: 36.63 (31.80)G2 26 week: 38.33 (28.49)G3 Pre-tx: 78.89 (16.87)G3 Post-tx: 68.06 (24.27)G1 vs. G3 Post-tx Differences: -13.23 (95% CI, -23.22 to -3.23), p <0.005, ES = -0.81 (95% CI, -1.42 to -0.20)G2 vs. G3 Post-tx Differences: -21.30 (95% CI, -31.60 to -12.19), p <0.001, ES = -1.33 (95% CI, -1.93 to -0.74)G1 vs. G2 Post-tx Differences: 8.67 (95% CI, -1.86 to 19.20), p = 0.947, ES = 0.53 (95% CI, -0.11 to 1.17)G1 vs. G2 12 week Differences: 14.50 (95% CI, 3.24 to 25.76), p = 0.994, ES = 0.88 (95% CI, 0.20 to 1.57)G1 vs. G2 26 week Differences: 13.68 (95% CI, 1.45 to 25.91), p = 0.986, ES = 0.83 (95% CI, 0.09 to 1.58) | PCL-CMean (SD)G1 Pre-tx: 61.85 (9.03)G1 Post-tx: 45.57 (15.88)G1 12 week: 46.96 (15.95)G1 26 week: 42.88 (15.96)G2 Pre-tx: 59.74 (9.09)G2 Post-tx: 40.63 (18.57)G2 12 week: 38.41 (17.98)G2 26 week: 40.83 (18.56)G3 Pre-tx: 60.30 (8.97)G3 Post-tx: 53.89 (11.77)G1 vs. G3 Post-tx Differences: -11.33 (95% CI, -16.18 to -6.48), p <0.001, ES = -1.26 (95% CI, -1.79 to -0.72)G2 vs. G3 Post-tx Differences: -11.23 (95% CI, -15.93 to -6.54), p <0.001, ES = -1.25 (95% CI, -1.77 to -0.72)G1 vs. G2 Post-tx Differences: -0.10 (95% CI, -5.18 to 4.98), p = 0.485, ES = -0.01 (95% CI, -0.57 to 0.55)G1 vs. G2 12 week Differences: 2.86 (95% CI, -2.58 to 8.29), p = 0.849, ES = 0.32 (95% CI, -0.29 to 0.92)G1 vs. G2 26 week Differences: -0.06 (95% CI, -6.02 to 5.90), p = 0.492, ES = -0.01 (95% CI, -0.67 to 0.65) | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Reich et al., 2004[84](#_ENREF_84) | G1: Risperidone0.5 to 8 mg/dayG2: Placebo | CAPS-2Mean Changes from Baseline Score (SD)G1: -29.6 (31.5)G2: -18.6 (12.3)p=0.015 | NR | NRNR |
| Resick et al., 2002[3](#_ENREF_3)Resick et al., 2003[125](#_ENREF_125)Resick et al., 2012[126](#_ENREF_126) | G1: CBT, cognitive processing therapyG2: CBT, exposure-based therapy (PE)G3: WL | CAPSMean (SD)G1 Pre-tx: 74.76 (18.77)G1 Post-tx: 39.08 (31.12)G1 3 mth FU: 42.21 (30.13G1 9 mth FU: 42.87 (31.06)G1 LTFU: 26.00 (23.35)G2 Pre-tx:76.60 (19.72)G2 Post-tx: 44.89 (33.52)G2 3 mth FU: 49.16 (32.86) G2 9 mth FU: 46.98 (33.68)G2 LTFU: 25.90 (26.05)G3 Pre-tx: 69.85 (19.57)G3 Post-tx: 69.26 (18.55)G3 3 mth FU: 69.26 (18.55)G3 9 mth FU: 69.26 (18.55)Posttreatment differences, p<.0001 3 mth FU differences, p<0.0001 9 mth FU differences, p<0.0001LTFU differences, NS | PSSMean (SD)G1 Pre-tx: 29.55 (8.62)G1 Post-tx:13.66 (11.05)G1 3 mth FU: 14.67 (11.79)G1 9 mth FU:15.13 (12.03)G1 LTFU: 9.68 (10.38)G2 Pre-tx: 30.09 (9.18)G2 Post-tx:17.99 (13.17)G2 3 mth FU:18.05 (13.78)G2 9 mth FU: 18.40 (13.98)G2 LTFU: 9.89 (10.52)G3 Pre-tx: 28.70 (7.33)G3 Post-tx: 27.77 (8.12)G3 3 mth FU: 27.77 (8.12)G3 9 mth FU: 27.77 (8.12)Only G1 vs. G2Posttreatment differences, NS 3 mth FU differences, NS9 mth FU differences, NSLTFU differences, p=0.06 | NRLost of PTSD Dx at PosttreatmentG1: 53%G2: 53%G3: 2.2%G1 vs. G2 Overtime, NSLTFUG1: 81.6G2: 58.7G1 vs. G2, NS |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Resick et al., 2015[127](#_ENREF_127), [128](#_ENREF_128) | G1: CPT-C (Includes only the cognitive component of CPT)G2: PCT  | PSS-IMean (adjusted for pre-tx values at post-tx, 6 month, and 12 month followup) (SE) G1 Pre-tx: 27.7 (7.4)G1 Post-tx: 23.0 (1.3)G1 6-month followup: 20.0 (1.5)G1 12-month followup: 19.0 (1.4)G2 Pre-tx: 27.1 (7.0)G2 Post-tx: 23.9 (1.3)G2 6-month followup: 21 (1.5)G2 12-month followup: 19.9 (1.4)Between group differences at Post-tx: t = 0.53, p = .60Between group difference at 6-month followup: t = 0.46, p = 0.65Between group differences at 12-month followup: t = 0.45, p = 0.66 | PCLS-S Mean (SD for Pre-tx and SE for Post assessments)Mean (SE) G1 Pre-tx: 59.3 (10.1)G1 Post-tx: 47.8 (1.9)G1 6-month followup: 46.8 (2.0)G1 12-month followup: 46.1 (2.3)G2 Pre-tx: 58.5 (10.6)G2 Post-tx: 51.2 (1.9)G2 6-month followup: 50.2 (2.0)G2 12-month followup: 48.6 (2.2)Slope (SE) and p value for ME regression model of PCLS-S with repeated measures. G1: -1 (.11), t = -8.98, p < .0001G2: -.6 (.11), t = -5.49, p < .0001Difference: -.4 (.16), t = 2.55, p = .012Between group effect sizes (d):Baseline to posttreatment: -.4Baseline to 6 months: -.4Baseline to 1 year: -.3 | NR |
| Rothbaum et al., 1997[45](#_ENREF_45) | G1: EMDRG2: WL | PSSMean (SD)G1 Pre-tx: 33.3 (8.7)G1 Post-tx: 14.3 (8.4)G1 3 mth FU: 9.8 (8.7)G2 Pre-tx: 39.0 (8.2)G2 Post-tx: 35.0 (5.9)Posttreatment G1 vs. G2, p<0.05 | IESMean (SD)G1 Pre-tx: 47.4 (15.0)G1 Post-tx: 12.4 (11.2)G1 3 mth FU: 5.7 (5.8)G2 Pre-tx: 48.9 (8.9)G2 Post-tx: 45.4 (6.4)Posttreatment G1 vs. G2, p<0.01 | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Rothbaum et al., 2005[13](#_ENREF_13) | G1: CBT, exposure-based therapy (PE)G2: EMDRG3: WL | Data reported in graphs | Data only presented in graphs | NRLoss of PTSD Dx at Posttreatment:G1: 95%G2: 75%G3: 10%G1&G2 vs. G3 p<0.001G1 vs. G2 p=0.108Loss of PTSD Dx at 6 months f/u:G1: 94.4%G2: 73.7%p=0.185 |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Ruglass et al., 2017 [143](#_ENREF_143) | G1: COPEG2: Relaspe PreventionG3: AMCG | CAPS-Severity Mean (SD)G1 Pre-tx: 55.38 (16.40)G1 Post-tx: 37.63 (23.76) G1 Followup 1 months: 29.50 (27.88)G1 Followup 2 months: 29.77 (26.14)G1 Followup 3 months: 28.40 (23.09)Change at 1 month: -27.12 (95% CI, -35.84 to -18.40), p <0.001Change at 3 months: -28.31 (95% CI, -36.01 to -20.60), p <0.001G2 Pre-tx: 57.70 (20.80)G2 Post-tx: 30.79 (27.54) G2 Followup 1 months: 29.00 (22.99)G2 Followup 2 months: 30.40 (22.83)G2 Followup 3 months: 28.91 (22.91)Change at 1 month: -25.38 (95% CI, -33.12 to -17.64), p <0.001Change at 3 months: -26.71 (95% CI, -34.28 to -19.14), p <0.001G3 Pre-tx: 46.39 (11.07)G3 Post-tx: 41.89 (24.52)Change: NR, nsTreatment X Time interactions at 1-month, p = 0.86In Group and Between Group Differences at 1 month and 3 months, ns | MPSS-SRMean (SD)G1 Pre-tx: 54.26 (24.60)G1 Post-tx: 19.40 (17.70)Change: -42.99 (95% CI, -56.30 to -29.68), p <0.001G2 Pre-tx: 57.49 (24.33)G2 Post-tx: 26.80 (20.87) Change: -31.51 (95% -40.64 to -22.38)G3 Pre-tx: 50.21 (23.58)G3 Post-tx: 40.00 (28.10)Change: NR, nsTreatment X Time Interaction, p <0.001Between group differencesG1 vs G3: -34.06 (95%CI -51.36 to -16.75), p <0.001G2 vs G3: -22.58 (95%CI -36.92 to -8.24), p =0.002G1 vs G2: -11.48 (95%CI -27.62 to 4.67), p =0.16 | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Sannibale et al. 2013[146](#_ENREF_146) | G1: IT (Integrated CBT for PTSD and AUD)G2: AS, (CBT for AUD plus supportive counseling) | CAPS-Severity Mean (SD)G1 Pre-tx: 68.00 (23.63)G1 Post-tx: 42.80 (26.45) G1 Followup 5 months: 40.39 (23.49)G1 Followup 9 months: 43.30 (28.25)G2 Pre-tx: 68.07 (21.10)G2 Post-tx: 46.71 (26.27) G2 Followup 5 months: 49.71 (22.90)G2 Followup 9 months: 41.19 (34.17)Treatment group\*time interactions ns | PDS Mean (SD)G1 Pre-tx: 33.07 (10.43)G1 Post-tx: 21.88 (14.66) G1 Followup 5 months: 20.88 (13.37)G1 Followup 9 months: 22.88 (16.68)G2 Pre-tx: 31.38 (10.43)G2 Post-tx: 24.18 (14.05) G2 Followup 5 months: 24.48 (16.00)G2 Followup 9 months: 20.81 (17.00)Treatment group\*time interactions ns | Remission NR Loss of Diagnosis based on CAPS, n (%)G1 Post-tx:20 (67)G1 Followup 5 months: 22 (73)G1 Followup 9 months: 21(70)G2 Post-tx: 21 (75)G2 Followup 5 months: 18(64)G2 Followup 9 months: 21 (75)Between group differences, β = -0.30, SE = 0.51, p = 0.554 |
| Sautter et al., 2015[131](#_ENREF_131) | G1: SAT G2: PFE | CAPSMean (SE)G1 Pre-tx: 85.93 (3.31)G1 Post-tx: 48.33 (3.71)G1 12 week followup: 44.64 (3.78)G2 Pre-tx: 82.93 (3.37)G2 Post-tx: 72.59 (3.79)G1 12 week followup: 71.93 (3.86)Treatment X Time Interaction at post-tx, t (80) = 4.95, p <0.0001Treatment X Time Interaction at 12 week followup, t (80) = 5.41, p <0.0001 | PCL-MMean (SE)G1 Pre-tx: 60.84 (2.12)G1 Post-tx: 42.16 (2.38)G1 12 week followup: 39.54 (2.48)G2 Pre-tx: 60.81 (2.17)G2 Post-tx: 53.91 (2.48)G2 12 week followup: 51.77 (2.53)Treatment X Time Interaction at post-tx, p = 0.0007Treatment X Time Interaction at 12 week follow, p =0.0006 | Remission/No Longer Met PTSD diagnostic criteria (based on CAPS lower than 45) at followupG1: 15 (52%)G2: 2 (7%)X2 (1) = 11.48, p = 0.0003 (Fisher’s exact test) |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Schnurr et al., 2003[139](#_ENREF_139) | G1: Exposure-based, trauma-focused group therapy (psychoeducation, cognitive restructuring, relapse prevention, and coping skills training) G2: Present-centered group Therapy (avoided trauma-focused references, cognitive restructuring, and other trauma-focused group therapy components) | CAPS Mean (SE)G1 Pre-tx: 80.41 (1.45)G1 7 mth FU: 74.00 (1.32)G1 12 mth FU: 72.79 (1.51)Change at 7 mths, p<0.001Change at 12 mths, p<0.001G2 Pre-tx: 82.01 (1.44)G2 7 mth FU: 76.03 (1.32)G2 12 mth: 74.82 (1.49)Change at 7 mths, p<0.001Change at 12 mths, p<0.001Treatment Effect, p=0.29Cohort Effect, p=0.01Treatment X Cohort Effect, p=0.04PTSD ChecklistMean (SD)G1 Pre-tx: 61.84 (0.91)G1 7 mth FU: 59.70 (0.84)G1 12 mth FU: 58.78 (0.89)Change at 7 mths, p<0.01Change at 12 mths, p<0.01G2 Pre-tx: 62.60 (0.94)G2 7 mth FU: 61.03 (0.84)G2 12 mth FU: 60.00 (0.88)Change at 7 mths, p>0.05Change at 12 mths, p<0.05Treatment Effect, NSTreatment X Cohort Effect, p=0.05 | NR | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Schnurr et al., 2007[138](#_ENREF_138) | G1: CBT, exposure-based therapy (PE)G2: PCT | CAPSBaselineMean (95% CI)G1: 77.6 (74.8 to 80.4)G2: 77.9 (75.1 to 80.6)Least Means (95% CI)Immediate posttreatment G1: 52.9 (47.7 to 58.0) G2: 60.1 (55.3 to 64.8) G1 vs. G2, P=.013 mth FUG1: 49.7 (44.7 to 54.7) G2: 56.0 (50.5 to 61.5) G1 vs. G2, P=.0476-monthG1: 50.4 (45.0 to 55.8) G2: 54.5 (49.3 to 59.7) G1 vs. G2, p =.21Treatment Effect, p=0.03Treatment X Time, p=0.37 | PCLBaseline Mean (95% CI)G1: 58.2 (56.0 to 60.3) G2: 57.1 (55.0 to 59.2)Least Square Means (95% CI) Immediate posttreatment G1: 41.6 (38.4 to 44.9) G2: 48.9 (45.8 to 52.0) G2G1 vs. G2, p<0.0013-monthG1: 43.5 (40.2 to 46.7) G2: 48.8 (45.3 to 52.4) at posttreatmentG1 vs. G2, p<0.0086-monthG1: 44.6 (41.2 to 48.1) G2: 48.5 (45.2 to 51.8) G1 vs. G2, p =0.049Treatment X Time, p=0.18 | Total remission, CAPs score <20G1: 15.2%G2: 6.9%OR (95% CI): 2.43 (1.10-5.37)Loss of diagnosis based on CAPSG1: 41.0%G2: 27.9%OR (95% CI): 1.80 (1.10-2.96) |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Schnyder et al., 2011[49](#_ENREF_49) | G1: Eclectic psychotherapyBEPG2: WL (Minimal attention) | CAPS Mean (SD)G1 Pre-tx: 78.6 (16.0)G1 Post-tx: 60.8 (32.8)G1 6 mth FU: 58.1 (30.5)G2 Pre-tx: 73.4 (19.2)G2 Post-tx: 66.4 (20.0)Group Effect, p<0.01 | NR | Remission Rates (CAPS score <20)PosttreatmentG1: 12.5% (n=2)G2: 0.0% (n= 0)6-month FollowupG1: 18.8% (n=3)G2: 0.0% (n= 0)Lost of PTSD Diagnosis (CAPS Total Score of <50)PosttreatmentG1: 12.5% (n=2)G2: 0.0% (n=0) |
| Simon et al., 2008[174](#_ENREF_174) | G1: Paroxetine12.5 to 62.5 mg/day G2: Placebo (Placebo and 5 additional sessions of PE) | SPRINTMean (SD)G1 Pre-tx: 16.11 (8.99)G1 Improvement Post-tx: 2.33 (5.24)G2 Pre-tx: 17.00 (7.65)G2 Improvement Post-tx:4.57 (7.24) p=NS | NR | Remission based on having a SPRINT score less than 6 at end pointG1: 33%G2: 14%NR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Sloan et al., 2012[17](#_ENREF_17) | G1: Sertraline 25 to 200mg/day G2: Venlafaxiene 37.5 to 375mg/day Sertraline 25 to 200mg/day | CAPSStandardized mean gain (95% CI)G1 Post-tx:3.18 (2.20, 4.16)G2 Post-tx: -0.14 (-0.39, 0.12)Condition X Time -17.96 (95% CI, -13.04, -22.89)individuals in the WET condition reported sign. Greater decreases in PTSD symptom severity across time than individuals in WL(p<.001)Hedge’s g (effect size):Post-tx: 3.49FU: 2.18 |   | Remission NRLoss of Diagnosis G1 Post-tx: 95%G2 Post-tx: 12%X2 = 37.66, p <0.001G1 18 week followup: 100%G2 18 week followup: 33%X2 = 22.49, p <0.001 |
| Sonne et al., 2016[186](#_ENREF_186) | G1: WETG2: WL | NR | HTQ (ITT)Mean (SE) G1 Pre-tx: 3.24 (0.04)G1 Post-tx: 3.02 (0.06)Difference: 0.22 (0.06), p <0.01, Effect size: 0.54G2 Pre-tx: 3.18 (0.05)G2 Post-tx: 3.05 (0.06)Difference: 0.13 (0.06), p =0.02, Effect size: 0.32Group difference for difference between pre- and post-treatment ratings: 0.09 (0.08), p = 0.27, Effect size: 0.22Group differences at follow up: Regression coefficient, B = 0.07 (95% CI, -0.09 to 0.22), Beta-coefficient = 0.06, SE = 0.08, p = 0.40 | Remission NRLoss of PTSD diagnosis NR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Spence et al., 2011[30](#_ENREF_30) | G1: CBT-mixed (Imaginal exposure, Coping skills, Cognitive processing)G2: WL | NR | PCL-CMean (SD)G1 Pre-tx: 60.78 (10.03)G1 Post-tx: 44.78 (17.29)G1 3 mth FU: 43.17 (17.89)G2 Pre-tx: 57.00 (9.69) G2 Post-tx: 51.79 (12.51)G2 3 mth FU: NRTreatment effect at 8 weeks, p<0.03 | Significant difference between groups at posttreatment for remission on PCL (p<0.01)Loss of diagnosis based on PCL at 3 monthsG1: 61%G2: NR |
| Stein et al., 2002[80](#_ENREF_80) | G1: Olanzapine10 to 20 mg G2: Placebo | CAPSMean Change from Baseline (95% CI)G1: -14.8 (SD=14.16)p<.05 G2: -2.67 (SD=10.55)p<0.05 | NR | NRNR |
| Tarrier et al., 1999[129](#_ENREF_129)Tarrier et al., 1999[130](#_ENREF_130) | G1: CBT, exposure-based therapyG2: CBT, cognitive restructuring,Cognitive Therapy | CAPS Global SeverityMean (SD)G1 Pre-tx: 71.14 (18.98)G1 Post-tx: 48.24 (30.25)G1 6 mth FU: 52.11 (23.78)G2 Pre-tx: 77.76 (14.95)G2 Post-tx: 50.82 (23.99)G2 6 mth FU: 50.21 (24.37)G1 vs. G2 differences, NS12-Month FollowupG1 Pre-tx: 71.76 (19.59)G1 12 mth FU: 45.16 (28.26)G2 Pre-tx:76.93 (15.40)G2 12 mth FU: 52.48 (24.09)G1 vs. G2 differences, NS | IES-IMean (SD)G1 Pre-tx: 23.86 (8.24)G1 Post-tx: 16.39 (10.04)G1 6 mth FU: 15.85 (9.26)G2 Pre-tx: 26.73 (7.80)G1 Post-tx:17.91 (10.29)G2 6 mth FU: 17.72 (10.40)G1 vs. G2 differences, NS12 Month FollowupG1 Pre-tx:24.68 (7.47)G1 12 mth FU: 15.67 (9.16)G2 Baseline: 26.55 (7.78)G2 12 mth FU: 18.68 (9.24)G1 vs. G2 differences, NS | NRPercent of Patients who were no longer PTSD cases PosttreatmentOverall: 50%G1: 59%G2: 42%6-MonthsOverall: 52%G1: 52%G2: 52%12-MonthsOverall: 61% |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Tarrier et al., 1999[129](#_ENREF_129)Tarrier et al., 1999[130](#_ENREF_130)(continued) |   |   | IES-AMean (SD)G1 Pre-tx: 22.69 (9.24)G1 Post-tx: 14.89 (9.09)G1 6 mth FU: 17.70 (10.74)G2 Pre-tx: 26.21 (7.55)G2 Post-tx: 19.61 (10.09)G2 6 mth FU: 18.31(9.66)G1 vs. G2 differences, NSIES-A12 Month FollowupG1 Pre-tx: 23.00 (9.36)G1 12 mth FU:18.00 (11.36)G2 Pre-tx:26.21 (7.93)G2 12 mth FU: 20.68 (10.97)G1 vs. G2 differences, NSPenn InventoryMean (SD)G1 Pre-tx: 47.28 (10.96)G1 Post-tx: 34.43 (14.69)G1 6 mth FU: 41.78 (12.50)G2 Pre-tx: 46.52 (12.98)G2 Post-tx: 36.09 (15.46)G2 6 mth FU: 37.24 (15.76)G1 vs. G2 differences, NS12 FollowupG1 Pre-tx: 47.52 (10.79)G1 12 mth FU: 41.04 (14.08)G2 Pre-tx: 47.03 (13.45)G2 12 mth FU: 38.39 (15.12)G1 vs. G2 differences, NS |   |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Taylor et al., 2003[133](#_ENREF_133) | G1: CBT, exposure-based therapyG2: EMDRG3: Relaxation Training | CAPSData only reported in graphsCompletersG1 Pre-Post changes, p<0.005G2 Pre-Post changes, p<.001G3 Pre-Post changes, p<0.005Intent to TreatNo significant differences | PTSD Symptom Severity Scale (part of PTDS)Intent to Treat Sample3 treatments did not differ (p>0.05) | NRNR |
| ter Heide et al., 2016[43](#_ENREF_43) | G1: EMDRG2: Stabilisation  | CAPSG1 vs. G2, d = -0.04, NS | HTQ, DSM-IVG1 vs. G2, d = 0.20, NSHTQ, totalG1 vs. G2, d = 0.29, NS | Remission CAPS Severity changeN (%)Improvement (> 10 points)G1:13/32 (40.6)G2: 13/31 (41.9)Loss of Diagnosis based on CAPSN (%)PosttreatmentG1 Post-tx:6 (19)G2 Post -tx: 9 (29)X2 (df) = 0.08 (1), p = 0.78 |
| Tucker et al., 2001[65](#_ENREF_65) | G1: Paroxetine20 to 50mg/dayG2: Placebo | CAPS-2Adjusted Mean Differences (95% CI), G1 vs. G2-10.6 (-16.2 to -5.0)TOP-8Adjusted Mean Differences (95% CI), G1 vs. G2-3.8 (-5.6 to -1.9) | DTS Adjusted Mean Differences (95% CI)G1 vs. G2-12.6 (-18.8 to -6.4)p<0.001 | CAPS-2 total score <2029.4% vs. 16.5% achieved remission; OR, 2.29; 95% CI, 1.24 to 4.23; p=0.008NR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Tucker et al., 2003[175](#_ENREF_175)Tucker et al., 2004[176](#_ENREF_176) | G1: Citalopram20 to 50 mg/dayG2: Sertraline50 to 200 mg/dayG3: Placebo | CAPSMean (SD)G1 Pre-tx: 91.0 (10.58)G1 Post-tx: 60.28 (26.15)G2 Pre-tx: 83.91 (17.28)G2 Post-tx: 42.09 (29.09)G3 Pre-tx: 94.20 (11.9)G3 Post-tx: 55.5 (29.07)Between group differences, NS | IESG1 Pre-tx: 50.04G1 Post-tx: 24.65G2 Pre-tx: 46.26G2 Post-tx: 17.16G3 Pre-tx: 53.8G3 Post-tx: 20.57Between group diffrences, p value NR | NRNR |
| Tucker et al., 2007[78](#_ENREF_78) | G1: Topiramate25 to 400mg/day; given 2 times a dayG2: Placebo | CAPSMean Percentage Change (SD)G1: -59.5 (35.9)G2: -45.5 (34.3)p=0.227 TOP-8Mean Percentage Change (SD)G1: -67.9 (30.0) G2: -41.6 (37.8)p= 0.023 | DTS Mean Percentage Change (SD)G1: -54.1(35.8) G2: -32.3(34.8) p=0.065 | CAPS score <20, NG1: 8G2: 4 p=0.295NR |
| Van Dam et al., 2013[262](#_ENREF_262) | G1: SWT plus TAU G2: TAU (regular intensivetreatment program for SUD based on CBT) | NR | PDSMean (SD)G1 Pre-tx: 30.4 (9.7)G1 Post-tx: 17.6 (12.0)G1 Followup 3 months: 23.5 (14.8)G2 Pre-tx: 28.3 (10.7)G2 Post-tx: 24.3 (9.1)G2 Followup 3 months: 21.7 (9.4)Treatment X time Interaction, F(3,34) = 1.92, p = 0.132, η2 = 0.059 | Full and Partial Remission (Remitted based on SCID), n (%)G1 Post-tx:9.2(48.2)G2 Post-tx: 1.8 (12)Between group difference not reportedFull PTSD Remission, (Remitted based on SCID), n (%)G1 Post-tx: 2 (22)G2 Post-tx: 1.2 (10)Between-group difference in PTSD diagnostic status (p = 0.06), less patients were diagnosed with PTSD in G1 vs. TAUNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| van den Berg et al., 2015[16](#_ENREF_16) | G1: PEG2: EMDRG3: WL | CAPSMean (SD or 95% CI)G1 Pre-tx:69.6 (14.9)G1 Post-tx: 37.8 (31.2 to 44.3)G1 6 month FU: 36.7 (30.1 to 43.4)G1 vs. G3 Post-tx, Effect size: 0.78t = -3.84, p <0.001G1 vs. G3 6 month, Effect size: 0.63t = -3.10, p =0.002G2 Pre-tx: 72.1 (17.6)G2 Post-tx: 40.3 (33.6 to 47.1)G2 6 month FU: 38.8 (31.9 to 45.6)G2 vs. G3 Post-tx, Effect size: 0.65t = -3.26, p =0.001G2 vs. G3 6 month, Effect size: 0.53t = -2.66, p =0.009G3 Pre-tx: 68.1 (15.9)G3 Post-tx: 56.5 (49.5 to 63.6)G3 6 month FU: 51.9 (44.9 to 58.9)G1 vs. G2 differences NS | PSS-SRMean (SD or 95% CI)G1 Pre-tx: 28.5 (8.0)G1 Post-tx: 16.1 (13.1 to 19.1)G1 6 month FU: 16.4 (13.4 to 19.4)G1 vs. G3 Post-tx, Effect size: 0.88t = -4.33, p <0.001G1 vs. G3 6 month, Effect size: 0.70t = -3.46, p =0.001G2 Pre-tx: 30.3 (7.8)G2 Post-tx: 16.1 (12.9 to 19.2)G2 6 month FU: 16.2 (13.0 to 19.3)G2 vs. G3 Post-tx, Effect size: 0.85t = -4.26, p <0.001G2 vs. G3 6 month, Effect size: 0.70t = -3.51, p =0.001G3 Pre-tx: 27.7 (8.9)G3 Post-tx: 25.8 (22.5 to 28.9)G3 6 month FU: 24.1 (20.9 to 27.4)G1 vs. G2 differences NS | Full Remission based on CAPS (score <20)N (%)G1 Post-tx: 15 (28.3)G2 Post-tx:9 (16.4)G3 post-tx:3 (6.4)G1 vs. G3 Post-tx, OR = 3.41, p = 0.006G2 vs. G3 Post-tx, OR = 3.92, p < 0.001G1 6 month FU: 14(26.4)G2 6 month FU: 8 (14.5)G3 6 month FU: 3 (6.4)G1 vs. G3 6 month FU, OR = 3.01, p = 0.003G2 vs. G3 6 month FU, OR= 2.76, p = 0.002G1 vs. G2 differences NSLoss of Diagnosis based on CAPSN (%)G1 Post-tx:30 (56.6)G2 Post-tx:33 (60.0)G3 post-tx: 13 (27.7)G1 vs. G3 Post-tx, OR = 3.01, p = 0.003G2 vs. G3 Post-tx, OR = 2.76, p = 0.002G1 6 month FU:31 (58.5)G2 6 month FU: 31 (56.4)G3 6 month FU:15 (31.9)G1 vs. G3 6 month FU, OR = 3.01, p = 0.003G2 vs. G3 6 month FU, OR= 2.76, p = 0.002G1 vs. G2 differences NS |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| van der Kolk et al., 1994[63](#_ENREF_63) | G1: Fluoxetine20 to 60mg/dayG2: Placebo | CAPSDifference in Improvement G1 vs. G2= 12.59ANCOVA ResultsF = -12.59, t = -2.67, p=0.0106 | NR | NRNR |
| van der Kolk et al., 2007[47](#_ENREF_47) | G1: EMDRG2: Fluoxetine10 to 60 mg/dayG3: Placebo | CAPS Mean (SD) (Post-tx & FU - ITT)G1 Pre-tx (1 mth CAPS): 71.7 (11.9)G1 Pre-tx (1 wk CAPS): 69.4 (12.7)G1 Post-tx: 32.55 (22.5)G1 FU: 25.79 (21.61)G2 Pre-tx (1 mth CAPS): 75.9 (15.6)G2 Pre-tx (1 wk CAPS): 73.7 (13.4)G2 Post-tx: 42.67 (22.11)G2 FU: 42.12 (15.83)G3 Pre-tx (1 mth CAPS): 74.5 (12.5)G3 Pre-tx (1 wk CAPS): 70.3 (13.0)G3 Post-tx: 43.55 (22.6)G3 FU: NAPosttreatmentTreatment effect, NSG1 vs. G3, NSG2 vs G3, NSG1 vs. G2, NSFollowupG1 vs. G2, p=0.005 | NR  | % asymptomatic, defined as CAPS <20G1: 28G2: 13G3: 10G1 vs. G2, p=0.17G1 vs. G3, p=0.09G2 vs. G3, p=0.726-month post-treatment f/u (intent-to-follow)G1: 58% G2: 0%G3: NAp<0.001Lost of PTSD Diagnosis, %G1: 76G2: 73G3: 59G1 vs. G2, p=0.82 G1 vs. G3, 0.16G2 vs. G3, 0.23 (G2/3)6-month post-treatment f/u (intent-to-follow)G1: 88% G2: 73%G3: NAp= 0.20 |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| van der Kolk et al., 2016[162](#_ENREF_162) | G1: NeurofeedbackG2: WL | CAPSMean (95% CI)G1 Pre-tx: 79.45 (72.86 to 86.04)G1 Post-tx: 42.95 (34.1 to 51.8)G1 1 month FU: 39.1 (29.69 to 48.51)G1 Pre-tx to 1 month difference: -40.42 (-48.67 to -32.12)d = -2.33G2 Pre-tx: 76.24 (69.13 to 83.36)G2 Post-tx: 66.49 (57.39 to 75.6)G2 1 month FU: 65.46 (55.83 to 75.1)G2 Pre-tx to -1 month difference: -10.78 (-19.1 to -2.48)d = -0.62Difference between groups at 1 month: -29.6 (-41.33 to -17.87)d = -1.71Treatment x time interaction: b = -10.45, t = -5.1, p <0.001 | DTSMean (95% CI)G1 Pre-tx: 67.28 (57.55 to 77.00)G1 Post-tx: 44.19 (35.76 to 52.63)G1 1 month FU: 36.5 (27.4 to 45.6)G1 Pre-tx to post-tx difference: -23.04 (-29.68 to -16.48)d = -0.92G1 Post-tx to FU difference: -7.69 (-9.89 to -5.49)d = -0.31G2 Pre-tx: 62.97 (52.47 to 73.48)G2 Post-tx: 58.21 (49.26 to 67.16)G2 1 month FU: 56.62 (47.09 to 66.15)G2 Pre-tx to post-tx difference: -4.76 (-11.6 to 2.07)d = -0.19G2 Post-tx to FU difference: -1.59 (-3.87 to 0.69)d = -0.06Difference between groups at post-tx: -18.32 (-27.82 to -8.82)d = -0.73Difference between groups at post-tx to FU: -6.11 (-9.27 to -2.94)d = -0.24treatment x time interaction: b = -1.52, t = -3.89, p <0.001 | Loss of PTSD Diagnosis, n (%) G1 post-tx: 72%G2 post-tx: 32%G1 1 month FU: 58%G2 1 month FU: 10%Posttx between group difference chi-sq: 7.38, p=0.007Baseline between group difference chi-sq: 9.47, p = 0.002 |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| van Emmerik et al., 2008[40](#_ENREF_40) | G1: CBT-Mixed Psychoeducation, prolonged exposure, imaginal exposure, exposure in vivo, cognitive exposureG2: SWT G3: WL | NR | IESMean (SD)G1 Pre-tx: 46.40 (12.32)G1 Post: 32.00 (20.32)G1 FU: 33.68 (22.18)G2 Pre-tx: 47.87 (13.82)G2 Post-tx: 34.32 (22.58)G2 FU: 33.68 (24.63)G3 Pre-tx: 49.14 (14.66)G3 Post-tx: 45.66 (13.65)G3 FU: 46.63 (13.17)Group X Time EffectG1 vs G2, p=0.62G1+G2 vs G3, p<0.01 | NRNR |
| Wells et al., 2014[19](#_ENREF_19) | G1: Metacognitive therapyG2: PEG3: WL  | NR | PDSMean (SD)G1 Pre-tx: 37.2 (8.93)G1 Post-tx: 10.4 (6.98)G1 3 month FU: 14.5 (16.2)Mean difference, post-tx: 26.8 (SE, 2.2), p <.005, (95% CI, 21.82 to 31.78)G2 Pre-tx: 32.80 (8.85)G2 Post-tx: 18.3 (13.31)G2 3 month: 16.5 (9.47)Mean difference, post-tx: 14.5 (SE, 4.61), p = 0.01, (95% CI, 0.08 to 24.92)G3 Pre-tx: 38.3 (8.74)G3 Post-tx: 39.2 (8.85)G3 3 month: NAMean difference, post-tx: -0.9 (SE, 0.75), p > 0.05, (95% CI, -2.60 to 0.80) | Loss of Diagnosis based on SCID-I/PG1: 1 (10%)G2:3 (33%)G3:NRRemission NR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Wells et al., 2014[19](#_ENREF_19)(continued) |   |   | Treatment X Time Interaction: F=21.70, p < .0005Hedge's g:G1 Pre-Post: 3.52G2 Pre-Post: .91G1 Pre-FU: 1.23G2 Pre-FU: 1.08ANCOVA group effect: F = 25.79, p < .0005G1 vs G3 Pre-Post: 28.16 (3.95), p < .0005, (95% CI, 18.05 to 38.28)G2 vs G3 Pre-Post: 17.71 (4.09), p = .001, (95% CI, 7.25 to 28.16)G1 vs G2 Pre-Post: 10.46 (4.05), p = .05, (95% CI, 0.13 to 20.79)ANCOVA group effects at followupG1 vs. G2: F = 0.16, p = 0.69IESMean (SD)G1 Pre-tx: 53.3 (8.87)G1 Post-tx: 9.9 (9.69)G1 3 month FU: 17.1 (19.31)Mean Difference, post-tx: 43.4 (SE, 2.77), p<0.0005, (95% CI, 37.13 to 49.68)G2 Pre-tx: 51.2 (8.16)G2 Post-tx: 23.7 (16.28)G2 3 month followup: 22.1 (16.21.19)Mean Difference, post-tx: 27.5 (SE, 5.91), p = 0.001, (95% CI, 14.13 to 40.87) |   |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Wells et al., 2014[19](#_ENREF_19)(continued) |   |   | G3 Pre-tx: 52.3 (12.98)G3 Post-tx: 51.3 (13.43)G3 3 month followup: NAMean Difference, post-tx:1.0. (SE, 3.12), p >.05, (95% CI, -6.06 to 8.06)Treatment X Time: F = 26.3, p < 0.005Hedge's g:G1 Pre-Post: 4.52G2 Pre-Post: 1.34G1 Pre-FU: 2.39G2 Pre-FU: 1.17ANCOVA group effect: F = 28.81, p < 0.0005G1 vs G3 Pre-Post: 41.43 (SE, 5.60), p < 0.0005, (95% CI, 27.59 to 56.26)G2 vs G3 Pre-Post: 27.02 (SE, 5.60), p <0.0005, (95% CI, 12.68 to 41.36)G1 vs G2 Pre-Post: 14.9 (SE, 5.62), p = 0.04, (95% CI, 0.52 to 29.28)ANCOVA group effects at followupG1 vs. G2: F = 0.62, p = 0.44 |   |
| Yeh et al., 2011[79](#_ENREF_79) | G1: Topiramate25 to 200mg/dayG2: Placebo | CAPSMean(SD)G1 Pre-tx: 78.76 (12.64)G1 Post-tx: 30.41 (30.90)G2 Pre-tx: 66.14 (22.63)G2 Post-tx: 35.78 (33.76)Between Group Change, p=0.49  | NR | NRNR |

| Author, Year | Intervention Groups | Clinician Administered  | Self-Administered  | Symptom RemissionLoss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Zlotnick et al., 2009[56](#_ENREF_56) | G1: Seeking Safety;G2: Usual carePsychoeducational group and individual case management and drug counseling  | CAPS Mean difference (95% CI)-2.30 (-13.81, 9.21) | NR | NRPercentage that Loss PTSD Diagnoiss based on CAPSPost-txG1: 52G2: 453 mth FUG1: 61G2: 576 mth FUG1: 57G2: 62 |
| Zohar et al., 2002[72](#_ENREF_72) | G1: Sertraline50 to 200 mg/dayG2: Placebo | CAPS-2Mean Change from Baseline (SD) G1: -18.7 (6.7)G2: -13.5 (6.6)Between Group Change, p=0.530 | NR | NRNR |

AMCG = active monitoring control group; ANOVA = analysis of variance; ANCOVA = analysis of covariance; CAPS = Clinician-administered PTSD Scale; CBT = Cognitive behavioral therapy; CI = confidence interval; CT = cognitive therapy; CPT = cognitive processing therapy; CPT-SA = Cognitive Processing Therapy for Sexual Abuse Survivors; DTS = Davidson Trauma Scale; EMDR = Eye movement desensitization and reprocessing; FU = Folow-up; HLS = health information control condition; IES = Impact of Event Scale; IRT = imagery rehearsal therapy; mg = milligram; MVA = motor vehicle accident; NA = not applicable; NF = Neurofeedback; NR= not reported; NS = not significant; OR = odds ratio; PCL-C =Posttraumatic Stress Disorder Checklist-Civilian; PCL-M = Posttraumatic Stress Disorder Checklist-Military; PCLS = Posttraumatic Stress Disorder Checklist Scale; PDS = Posttraumatic Diagnostic Scale; PE= prolonged exposure; PTSD = post-traumatic stress disorder; Pre-tx = pretreatment; Post-tx = Posttreatment; PSS= PTSD Symptom Scale; PSS-SR= PTSD Symptom Scale-Self-report; PTSD= Post-Traumatic Stress Disorder; RMANOVA, repeated measures analysis of variance; SCID =; SD = standard deviation; SE = standard error; SI-PTSD or SIP= Structured Interview for PTSD; SPRINT= Short PTSD Rating Interview; SSRIs = Selective serotonin re-uptake inhibitors or serotonin-specific reuptake inhibitor; STAIR = Skills Training in Affect and Interpersonal Regulations; SWT = strutured writing therapy; TOP-8 = Treatment Outcome PTSD Scale; VRET = virtual reality exposure therapy.